Microencapsulation of a Connexin-43 Mimetic Peptide as a Novel Wound Healing Agent in an Ocular Injury Model by Moore, Keith Brian




Microencapsulation of a Connexin-43 Mimetic
Peptide as a Novel Wound Healing Agent in an
Ocular Injury Model
Keith Brian Moore
University of South Carolina
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biomedical Commons
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Moore, K. B.(2013). Microencapsulation of a Connexin-43 Mimetic Peptide as a Novel Wound Healing Agent in an Ocular Injury Model.
(Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/530
 
Microencapsulation of a Connexin-43 Mimetic Peptide as a Novel Wound Healing Agent 








Bachelor of Science 






Submitted in Partial Fulfillment of the Requirements 
 




College of Engineering and Computing 
 






Jay Potts, Major Professor 
 
Richard Goodwin, Committee Member 
 
Robert Gourdie, Committee Member 
 
James Blanchette, Committee Member 
 































 I would like to dedicate this work to three people without whom I don’t think this 
would be possible; Kelly Moore, Carroll Moore, and David Campbell.  Each gave me 




 I would like to acknowledge and thank Dr. Jay Potts for allowing me to work in 
his laboratory while obtaining my PhD.  Without his mentorship and guidance this is not 
possible.  I would also like to thank the University of South Carolina and the associated 
faculty and staff of the Biomedical Engineering program, especially my committee 
members Dr. James Blanchette, Dr. Richard Goodwin, and Dr. Robert Gourdie.  The 
Biomedical Engineering program gave me a chance and allowed me to pursue this degree 
while switching disciplines from my undergraduate work in Biochemistry.  For this 
opportunity I am most grateful.  
Finally I would like to thank my lab mates Na Li and Adam Vandergriff as well 
as all of my fellow graduate researchers and friends at the school of medicine and the 




 Corneal transplantation and related surgical procedures are areas of tissue 
replacement which have seen promising advances.  Currently, cornea transplants are one 
of the most common surgical procedures, with approximately 40,000 occurring each year 
in the United States.  Still, problems exist with a 20% rejection rate, post surgical 
infections, and the need for a constant supply of donors.  The ability to safely and quickly 
heal and regenerate corneal epithelia fills an area of advancement in regenerative 
medicine, with implications reaching beyond the scope of vision therapies toward healing 
of a wide range of tissues and wounds. In vivo corneal wounds were created in rats 
through a surgical procedure chemically loosening and mechanically removing the 
epithelium from the corneal surface. Our study applies a synthetically developed peptide 
capable of promotion of wound healing and epithelial regeneration. The alpha-carboxy 
terminus 1 (αCT1) peptide is a 25 amino acid peptide from the C-terminus of connexin 
43, modified to promote cellular uptake.  Previous studies applying αCT1 to excisional 
wounds in rats produced resulting tissue having an overall reduced level of scar tissue 
and decreased healing time, compared to controls.  Upon entering the wound site, the 
peptide acts as a competitive inhibitor to the ZO-1-Cx43 interaction.  In doing so, the 
formation of gap junctions during healing is altered.  Here we first characterized the 
development and synthesis of alginate based microcapsules, designed to deliver αCT1 in 
a controlled and sustained release.  We hypothesized sustained release of αCT1 would 
enhance the peptides innate wound healing ability beyond previous results. An alginate-
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poly-l-ornithine pH 4.3 microcapsule capable of delivery of 150µM of peptide over 48hrs 
was ultimately produced.  Both directly applied αCT1 in a pluronic gel system and 
microencapsulated αCT1 were tested in two studies of in vivo corneal wound injuries 
using normal and STZ type I diabetic Sprague Dawley rats.  Data derived from RT-PCR, 
confocal immunohistochemistry, inflammatory H&E scoring, western blotting, Elisa 
protein analysis, and fluorescent wound measurements indicated a significant increase in 
wound healing speed when αCT1 was applied at a 150µM concentration.  The 
application of 150µM αCT1 alginate-poly-l-ornithine pH 4.3 microcapsules further 
increased corneal wound healing rate beyond those seen when using αCT1 alone.     
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CHAPTER 1: INTRODUCTION 
Cell-to-Cell Adhesion and Connexins 
Connexins, also known as gap junction proteins, are a group of transmembrane 
proteins functioning in the creation of gap junctions.  Gap junctions play multifunctional 
roles, acting as connecting channels between adjacent cells to transmit electrical impulses 
and mediate the passage of small molecules, ions, metabolites, and second messengers.  
Gap junctions form through the assembly of six connexin proteins across a cell 
membrane.  The six connexins may be of the same type (homomeric) or of different types 
(heteromeric), with nomenclature based on molecular weight (Herve et al 2004).  Initially 
connexins are synthesized by ribosomes bound to the endoplasmic reticulum.  Once 
translated, the connexins are oligomerized and assembled into six unit connexons 
(Bennett et al 2004).  Post assembly, the connexons are inserted into the plasma 
membrane of the cell, forming a hemichannel. Hemichannels then bond with 
corresponding hemichannels from adjacent cells.  Once two hemichannels are bound a 
functional gap junction is formed. The hemichannel-hemichannel interactions may be 





Figure 1.1 Illustration of formation of gap junction between adjacent cells. Image 
obtained from http://cellbiology.med.unsw.edu.au/units/science. 
 
Each connexin consists of nine domains (two extracellular, four transmembrane, 
three cytoplasmic) of which all but the C-terminus and cytoplasmic loop are highly 
conserved between each type (Dbouk et al 2009).  The variability in these two regions of 
the connexins allow for differences in functionality.  Of interest in this research is the C-
terminus region of Connexin 43.  Initially gap junctions were thought to only function in 
simple cell to cell transport.  Now, many different interactions involving varying protein 
to protein binding with the gap junction nexus is thought to create changes in function 
and regulation.  Connexins have been found to interact with other cellular junction 
associated molecules such as cadherins (adherens junctions) and zonula occludens (tight 
junctions) as well (Dbouk et al 2009; Weiss 2001; Kowalczyk et al 1999).  Through these 
interactions it is thought a complex system exists to regulate tight junctions and cell-to-
cell connections. 
The cytoplasmic tight junction protein ZO-1 binds at the PDZ-2 domain with the 
Cx43 C-terminus end at the DDLEI sequence (Duffy et al 2002).  Other alpha type 
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connexins such as connexin 45 have also been shown to also bind to ZO-1, possibly 
stabilizing the Cx43-ZO-1 interaction (Laing et al 2001). The exact role of this 
interaction is unknown, but it is theorized that the relationship may play a key role in 
trafficking of molecules (Toyofuku et al 1998) for gap junction formation or as a base 
scaffold in gap junction formation (Duffy et al 2002).  Connexins have been found to 
remain in an open state in response to pathology induced stress, including ischemia and 
hypoxia (Evans et al 2012).  Furthermore, open hemichannels were shown to be 
associated with specific disease states such as cardiac arrhythmia and myocardial 
infarction. Recent work by Rhett et al 2011 indicated that the Cx43-ZO-1 interaction 
occurs not only at the gap junctions of the plasma membrane, but also the free connexons 
of the perinexus. Additional binding of connexins with tight junction associated proteins 
was found to occur between occludin-Cx26 and occludin-Cx32 in hepactocytes as well as 
claudin-Cx32 (Kojima et al 2001).  Adherens junction proteins Wnt-1 and β-catenin 
associate with Cx43 to regulate communication, as shown in cardiac myocytes. (Ai et al 
2000).  A summary list of other known capable connexin 43 interacting or co-localizing 
proteins includes Lin-7, α-catenin, p120, N-cadherin, src, PKCα, DMPK, MAPK, 
P38MAPK, tubulin, F-actin, drebrin, caveolin-1, clathrin, ubiquitin, CIP 62, and NOV 
(Herve et al 2004).     
 Wound Healing and the Cornea 
 In this work the αCT1 peptide was evaluated for its therapeutic potential in 
corneal injury models using both normal and type I diabetic rats. The cornea is the 
nonvascular outer layer of the eye.  Five layers comprise the cornea, with the outermost 
being the epithelium, accounting for approximately 10% of the thickness.  Roughly five 
to six cells thick, the epithelial layer serves to block entry of materials into the eye, 
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absorbs oxygen, and senses pain to protect the eye from damage.  The cornea epithelial 
layer is attached to a basement membrane.  The second layer of the cornea is the 
Bowman’s layer, which is a transparent sheet of collagen.  This layer may be scarred, 
affecting vision.  The third and thickest (90%) layer is the stroma.  Made up of roughly 
78% water and 16% collagen the stroma gives the cornea its flexibility and shape.  Fourth 
is the Descemet’s membrane which is a collagen membrane acting to protect against 
infection.  The fifth layer is the single cell thick, endothelial layer. The endothelium 
regulates and removes leaked fluid from the stroma to prevent impaired vision, swelling, 
and blurring.       
Typical wound healing of the skin consists of three main overlapping phases: 
inflammation, tissue formation, and tissue remodeling (Martin 1997).  Inflammation 
begins immediately following wound formation, where fibroblasts and macrophages are 
attracted to the injured site (Gurtner et al 2008).  Damaged extracellular matrix (ECM) 
and contaminating microorganisms are phagocytosed.  During inflammation TGF-β and 
other ECM proteins begin to infiltrate the wound as well.  Several hours after injury 
epithelialization begins.  Clotted blood is removed as well as intercellular desmosomes, 
allowing cellular movement into the wound.  Within 1-2 days epidermal cells proliferate 
and migrate into the wounded area.  As reepithelization occurs, basement membrane 
proteins reorder and epidermal cells begin attachment.  Approximately 4 days after injury 
new granulation tissue enters the wound.  TGF-β stimulates fibroblasts to form new 
ECM.  At this stage neovascularization also occurs, with VEGF and fibroblast growth 
factor inducing addition of new blood vessels to wound space.  Once the ECM is 
reformed the fibroblasts stop producing collagen and the granulation tissue is replaced 
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with an acellular scar (Schultz et al 1991).  After 2 weeks wound contraction and ECM 
reorganization occur.  Fibroblasts convert to myofibroblasts and microfilaments enter the 
healing tissue.  The wound is then pulled from the edges to contract.  Remodeling 
continues for up to 12 months after injury.  At this point, wounded tissue has 
approximately 70% of the strength of the previously uninjured skin (Martin 1997). 
The cornea, with its avascular structure, follows a different healing process than 
that of the skin. A series of overlapping processes occur in a rapid fashion, beginning 
immediately after injury. Following the epithelial injury, a cascade of cytokines 
(including IL-1 and PDGF) initiate keratocyte apoptosis (Wilson et al 2001).  Growth 
factor cytokines are then released by the lacrimal glands, which trigger keratocyte 
proliferation and migration from the stroma (Zeiske et al 2001).  This is followed by 
myofibroblast proliferation and migration to the wound site. Additional cytokines, such 
as TGFβ are released, triggering collagen production and remodeling (Netto et al 2005).  
Inflammatory cells migrate to the wounded area and stromal remodeling occurs, if 
necessary (Ye et al 2000).  As the epithelial layer completes closure the inflammatory 
cells undergo apoptosis and the keratocytes return to their original state (Dupps and 
Wilson 2006). In addition, the limbus of the corneal epithelium is a source of stem cells 
capable of transmigrational proliferation, but is not known to be necessary for 
reepithelialization after wounding (Dua et al 2010).  While the outline of the healing 
process is known, many of the details of the process and associated factors are still under 




 Epithelial-mesenchymal transition, or EMT, is a series of events where an 
epithelial cell is changed into a mesenchymal cell.  In this work we examine the role of 
this pathway in response to the αCT1 peptide in corneal wound healing. EMT occurs in 
many biological processes, beginning in early embryonic development, where it is 
responsible for the formation of the mesoderm and induction of the neural crest (O’Quinn 
et al 2011).  EMT has also been found to occur in other seminal events such as organ 
development, tumor cell metastasis, and fibrosis of the lungs, kidneys, heart, and liver 
(Chapman 2010; Guarino et al 2009; Kalluri et al 2003; Lee et al 2006).  During fibrosis 
of major organs epithelial cells undergo EMT to become mesenchymal cells, 
translocating to areas of inflammation.  Upon arriving, the mesenchymal cells are thought 
to act as fibrotic cells, depositing collagen matrix.  Excess matrix deposition leads to 
scarring at sites of chronic inflammation and further tissue injury (Chapman 2010; 
Guarino et al 2009). 
To understand the pervasiveness of this cellular event, the characteristics of each 
cell type must be understood.  Epithelial cells are cuboidal, rigid cells which form sheets 
with strong cell-cell interactions.  Typically epithelial cells form barriers for organs and 
tissues.  Epithelial cells are immobile and tightly bound by tight junctions, adherens 
junctions, gap junctions, and desmosomal junctions.  Mesenchymal cells on the other 
hand are very different.  They have a non-rigid shape, loose and short lived cell-cell 
interactions, and are mobile.   
The EMT process is a biological method of cellular rearrangement and repair of 
damaged tissue where immobile cells used for structural integrity and boundary 
formation may be mobilized to an area of need (Lim et al 2012).  Once the EMT process 
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is complete the mesenchymal cells convert back to epithelial cells in a reverse process 
called MET, or mesenchymal-epithelial transition.  Typically the EMT process is tightly 
regulated by the body, as in embryogenesis.  Unregulated, EMT can lead to disease 
states, such as in tumorigenesis and cancer.   
 There are several markers to identify EMT.  On the molecular level β–catenin 
localizes in the nucleus, while the presence of vimentin, N-cadherin, snail, slug, and twist 
all increase (Guarino et al 2009).  Phenotypically there is a noticeable increase in cellular 
motility, three-dimensional invasion, and apoptosis resistance.   The signaling pathway to 
initiate EMT has not been fully mapped, and the activation/regulation process is still 
being investigated.  However, multiple signaling factors have been discovered.  It is 
thought that TGFβ and Snail1 are central to EMT events (Mirza et al 2012; Vogelmann et 
al 2005).  Metalloproteinase-3 (MMP-3) is a Snail1 activator.  The presence of MMP-3 in 
epithelial cells activates Rac1 production, which in turn activates the production of 
reactive oxygen species (ROS) (Radisky 2005).  The ROS then activates Snail1 
production.  Snail1 genes induce EMT by the regulation of cell adhesion and cellular 
migration.  ILK (integrin-linked kinase) has been found to activate Snail1 as well.  TGFβ 
is an important cytokine, which when bound to cell surface receptors can trigger a 
cascade of cellular responses to activate EMT.  One central factor activated is β-catenin.  
When β-catenin is bound it enhances cell-cell adhesion by E-cadherin (Brembeck et al 
2004; Chu et al 2004).  TGFβ stimulation causes β-catenin to detach and move to the 
nucleus where it activates transcription of EMT genes (Chapman 2010).  Cadherins are 
transmembrane proteins responsible for creating adherins junctions.  E-cadherin typically 
creates stronger bonds than those of N-cadherins.  During EMT E-cadherin is down 
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regulated while N-cadherin is up regulated post β-catenin stimulation (Chapman 2010). 
Activation of these transcriptional factors in the nucleus leads to a loss of strong cell-cell 
interactions, releasing the epithelial cell from the basement membrane and surrounding 
cells.  The epithelial cell then rearranges the F-actin stress fibers and expresses filopodia 
and lamellapodia in the mesenchymal state (Lee et al 2006).  Finally, transcription is 
activated to produce mesenchymal markers. The epithelial cell is now a phenotypic and 
molecular match to a mesenchymal cell. 
 Previous work in our lab with BMSCs has indicated that EMT may be induced ex 
vivo.  In particular work has shown that different cell lines may be induced to undergo an 
EMT event in collagen gels.  Rabbit lens epithelial cells seeded on dialyzed collagen gels 
can be primed to undergo EMT (Data not shown).  Below is a summary of known EMT 
regulated genes and their specific roles (Table 1.1) and a pathway map showing the 
regulation connections of some of the genes selected in the studies outlined in chapters 3 










Table 1.1 Summary of genes associated with the EMT pathway and their functional 
roles. Data from pathway analysis using a Quiagen RT
2
 EMT assay and related 
manufacturer information. 
Function Associated Genes 
Genes Up-Regulated 
During EMT 
Ahnak, Cald1, Camk2n1, Cdh2, Col1a2, Col3a1, Col5a2, Fn1, 
Foxc2, Gng11, Gsc, Igfbp4, Itga5, Itgav, Mmp2 (Gelatinase A), 
Mmp3, Mmp9 (Gelatinase B), Msn, Serpine1 (PAI-1), Snai1, 
Snai2, Snai3, Sox10, Sparc, Steap1, Tcf4, Timp1, Tmeff1, 




Cav2, Cdh1, Dsp, Fgfbp1, Il1rn, Krt19, Mitf, Ocln, Rgs2, Spp1 




Akt1, Bmp7, Col3a1, Col5a2, Ctnnb1, Dsp, Erbb3, F11r, Fgfr2, 
Foxc2, Fzd7, Gsc, Jag1, Krt14, Map1b, Mitf, Nodal, Notch1, 
Ppp3r1, Ptp4a1, Smad2, Snai1, Snai2, Sox10, Tgfβ2, Tgfb3, 
Tmeff1, Twist1, Vcan, Wnt11, Wnt5a, Wnt5b. 
 
Morphogenesis Ctnnb1, Foxc2, Jag1, Rac1, Smad2, Snai1, Sox10, Tgfβ1, Tgfβ2, 
Tgfb3, Twist1, Wnt11, Wnt5a. 
Cell Growth & 
Proliferation 
Akt1, Bmp7, Cav2, Ctnnb1, Egfr, Erbb3, Fgfbp1, Foxc2, Igfbp4, 




Cald1, Cav2, Egfr, Fn1, Itgb1, Jag1, Msn, Nodal, Pdgfrb, Rac1, 
Stat3, Tgfβ1, Vim. 
Cytoskeleton Cav2, Krt7, Plek2, Rac1, Vim 
Extracellular Matrix 
& Cell Adhesion 
Bmp7, Cdh1, Cdh2, Col1a2, Col3a1, Col5a2, Ctgf, Ctnnb1, 
Dsc2, Egfr, Erbb3, F11r, Fgfr2, Fn1, Foxc2, Ilk, Itga5, Itgav, 
Itgb1, Mmp2 (Gelatinase A), Mmp3, Mmp9 (Gelatinase B), 
Ptk2, Rac1, Serpine1 (PAI-1), Spp1 (Osteopontin), Tgfb1, 
Tgfβ2, Timp1, Vcan. 
Transcription 
Factors 
Ctnnb1, Esr1 (ERa), Foxc2, Gsc, Mitf, Notch1, Sip1, Smad2, 






Figure 1.2 Pathway map showing the regulatory connections of sample genes from the 
EMT pathway. Genes shown here were selected to represent those used in chapters 3 and 
4. GLUT4 is represented here by SLC2A4. 
Microencapsulation and Drug Delivery Systems  
 For controlled release of αCT1, microcapsule delivery was investigated. 
Microencapsulation is a technique in which small particles are coated with a material to 
provide a secondary property of use.  Typically the secondary property is controlled 
release or protection of the encapsulated material.  Microencapsulation systems rely on 
diffusion of the encapsulated materials from the inner core to deliver the drug and have 
been shown to successfully deliver many different bioactive substances such as peptides, 
proteins, enzymes, and antibiotics. Many methods exist for encapsulation including 
emulsification, solvent evaporation, pan coating, electrospray encapsulation, and pulse-
flow to name a few (Gaete et al 2008; Yang et al 2001).  Microcapsules can vary in shape 
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according to synthesis procedures, with spheres, rods, cubes, and corrugated patterns 
reported (Enayati et al 2009). The encapsulation technique in this work is the electrospray 
method using sodium alginate polymer cores. 
Electrohydrodynamics refers to methods of fabrication of polymeric materials 
using electrically charged fluids.  Examples of polymer materials that may be used 
include sodium alginate (SA), chitosan, poly-caprolactone (PCL), poly-lactic-co-glycolic 
acid (PLGA), poly-ethylene oxide (PEO), poly-ethylene glycol (PEG), poly-l-lysine 
(PLL), poly-l-ornithine (PLO), and poly-lactic acid (PLA)  (Casper et al 2005; Chew et al 
2005; Xu et al 2006; Chakraborty et al. 2009; Zhang et al 2009; Takka et al 2010).  Each 
polymer possesses its own unique properties such as biocompatibility, charge, reactivity 
with the drug, and viscosity in solution which affect the appropriateness of application.   
Within the field of electrohydrodynamics, two main categories exist: electrospinning and 
electrospraying.  Similar in methodology, each uses one of a variety of polymers placed 
in a positively charged syringe attached to a high voltage generator.  Using a device to 
control flow rate, such as a syringe pump or driver, the polymer is extruded to a grounded 
material.  The flowing polymer, which is an electrically conductive solution, passes 
through the electrical potential difference.  With the application of flow, gravity, and an 
electric polarization stress, a cone jet is formed at the needle tip (Jaworek and Krupa 
1999a).  Typically, without these forces, liquids will form a droplet that is geometrically 
controlled by the surface tension of the solution and the pull of gravity (Paine et al 2007).  
The cone jet is a conically shaped formation at the needle tip, to which charged particles 
of liquid exist at the apex of the cone. Once a minimally stable level of both flow and 
electrostatic voltage are present (dependent on the materials) the charged particles 
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separate from the apex and break apart into reproducible droplets (Jaworek and Krupa 
1999b). These droplets are then collected using a grounded device or solution, as nano or 
microcapsules. With electrospinning, the grounded device is typically a solid collector of 
various shape or size.  Electrospraying can involve extrusion into a grounded solution or 
onto a grounded surface.  Both electrospinning and electrospraying are gaining interest as 
methods of delivery of drugs and other activators of biological processes because they 
can be easily altered, thus changing release rates and pharmacokinetics. Other methods of 
drug delivery may require additional processing steps involving heat, pressure, shear 
stress, or reactive secondary chemicals which can degrade or decrease the functionality of 
the drug (Enayati et al 2011).  Thus, the electrospray method is ideal in its lack of these 
negative procedures.  
 Alginate is a polymer commonly used in microencapsulation for its 
biocompatibility and is used here as a base microencapsulating material.  Extracted from 
the cell walls of brown seaweeds, alginate is popular due to ease of obtainability and 
production at a low cost (Orive et al 2006; Zhang et al 2009, 2010).  Sodium alginate is a 
straight-chain, hydrophilic, polyuronic acid composed of 1→4 linked β-D-mannuronic 
acid and α-L-guluronic acid residues (Lee and Mooney 2012).  The alginate, in addition 
to mannuronic acid, is also composed of guluronic acid.  When crosslinked to cations, 
such as calcium, a hydrogel is formed (Arghya et al 2010; Zhang et al 2008).  Figure 1.3 







Figure 1.3 Chemical structure of sodium alginate polysaccharide with both guluronic (G) 
and mannuronic acids (M) shown.  Image produced by the Food and Agriculture 
Administration of the United Nations. 
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CHAPTER 2: SYNTHESIS AND CHARACTERIZATION OF A DRUG 
DELIVERY SYSTEM FOR THE αCT1 PEPTIDE 
2.1 Abstract 
A need exists to prolong the release of rapidly metabolized peptides of a low 
molecular weight, while delivering this peptide without environmental interference.  
Previous studies have used Bovine Serum Albumin as a model peptide to study release 
characteristics from alginate microcapsules.  BSA is 66kDa in size, while the peptide of 
interest here, connexin-43 carboxyl-terminus mimetic peptide (αCT1), is 3.4kDa; a large 
difference in terms of release.  Such a change in size results in a much different set of 
release parameters.  The overall goal is a sustained release over a 24+ hr period, which 
would allow prolonged application of the peptide to a wound site in order to investigate 
therapeutic effects.  As a result, diffusion methods using sodium alginate microcapsules, 
with additional poly-l-lysine (PLL) and poly-l-ornithine (PLO) coating, have been 
explored.  We first aimed to establish and characterize our size distribution parameters 
through a set of parametric tests. Variations in polymer coating, change in pH, and 
loading ratio have previously been shown to effect release using model compounds.  Here 
we test specific changes in these parameters to show effects on the release of αCT1.  
Additionally, the microcapsules were attached to several biomaterials and surgical 
implants by ultraviolet crosslinking to study effectiveness of attachment and delivery.  
Analysis and measurements using phase contrast microscopy, atomic force microscopy 





Drug delivery systems (DDS) may be created in the nano and micro scale.  
Depending on the disease state and desired target to which the drug is to be delivered, a 
number of factors must be evaluated.  Each DDS has inherent properties that make it 
ideal for certain applications.  For example, in vivo interactions with the DDS may be 
altered based on the size, geometry, material properties (hydrophobicity, hydrophilicity, 
charge, etc.), biocompatibility, degradation rate, density, transport characteristics, and 
clearance rate of the delivery material (Chew et al 2006; Pham et al 2006; Rutledge et al 
2007; Chakraborty et al 2009). 
Within the electrospraying method, multiple techniques exist for encapsulating 
drugs.  One method comprises synthesis of microcapsules and placement in drug 
containing solutions, allowing adsorption of the drug onto the microcapsule surface 
(Chakraborty et al 2009). A second method involves simultaneous spraying of an 
encapsulating polymer of one charge with a drug containing polymer of the opposite 
charge, thus creating a multilayered sphere (Langer et al 1969; Enayati et al 2011).    
Drugs may also be dissolved and mixed with polymers prior to capsule formation, 
creating capsules in one of two ways.  First the mixed drug/polymer has a volatile solvent 
added to the solution, which is removed by evaporation between extrusion and collection.  
Once removed the nano/microcapsule is solidified and stabilized (Wu et al 2009). 
Second, the mixed drug/polymer may be extruded into an ionic solution, which acts to 
chemically bind and stabilize the created capsules (Xu et al 2006, 2007; Zhang et al 
2010a). This method of electrospray microencapsulation is employed in this research, 
using calcium chloride.  Another method is coaxial electrospraying.  This process uses a 
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syringe within a syringe to extrude a drug containing core within a polymer shell layer 
(Hwang et al 2008). 
 Alginate is a polymer commonly used in microencapsulation for its 
biocompatibility.  Extracted from the cell walls of brown seaweeds, alginate is popular 
due to its lack of toxicity, ease of obtainability, and low cost production (Orive et al 
2006; Zhang et al 2009, 2010).  Structurally alginate is, “A straight-chain, hydrophilic, 
colloidal, polyuronic acid composed primarily of anhydro-β-D-mannuronic acid residues 
with 1→4 linkage.” (Mbanaso & Roscoe 1982; Draget et al 1989). The alginate, in 
addition to mannuronic acid, is composed of guluronic acid.  When sodium alginate is 
crosslinked to cations, such as calcium, a hydrogel is formed (Arghya et al 2010; Zhang 
et al 2010b).  Low w/v mixtures (1.5-3%) of sodium alginate have been shown to have 
sufficient strength and compatibility in vitro when used with living cells (Lin et al 2008; 
Zhang et al 2010b).  Many polymers, previously listed in chapter 1, have been explored 
for use in microencapsulation, with the hope of finding an ideal solution that provides 
biocompatibility, the ability to form stable capsule membranes, and ease in control of the 
release properties. Promising results have been shown in both synthesis and biological 
experiments using PLL and PLO (Rosinski et al 2005; Calafiore et al 1999).  Here we 
explore the use of these polymers in low concentrations as coatings for the sodium 
alginate based microcapsules. 
In this work the connexin-43 carboxyl-terminus peptide (αCT1) has been 
microencapsulated in sodium alginate to create a controlled drug delivery system.  The 
αCT1 peptide is a biotinylated 25 amino acid sequence from the C-terminus of connexin 
43 originally synthesized in the laboratory of Dr. Robert Gourdie (Ghatnekar et al 2009).  
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Connexins play a key role as mediators in both cell growth and cell death, function in the 
immune response, hematopoiesis, and development of progenitor cells (Oviedo-Orta et al 
2004; Vinkin et al 2011).  An antennapedia section exists to aid in cellular uptake of the 
peptide without inducing genetic activity.  For analysis, a biotin tail has also been 
incorporated into the peptide.  A control peptide has also been created with the inactive 
16 amino acid antennapedia portion conserved and the active sequence reversed.  
Previous research conducted using αCT1 has shown significant effects on reduction in 
the formation of skin scars, wound healing, and gap junction remodeling upon ventricular 
injury (O’Quinn et al 2011).  An exact model of the peptide action has yet to be fully 
elucidated, but research has shown possible interaction with gap junction remodeling and 
connexin 43 interaction with zonnula occludin-1 (ZO-1) as points of interest (Rhett et al 
2008, 2011).  Subsequent research has shown an effect of αCT1 on the interaction 
between connexin 43 gap junctions and ZO-1 (Hunter et al 2005; Ghatnekar et al 2009,).  
Rapid metabolism of the peptide (~2 hours) has prevented previous studies of the long 
term effects in these injury models.     
2.3 Materials and Methods 
Electrospray Method of Microencapsulation 
Sodium alginate (Sigma-Aldrich catalog#A0682) was mixed under sterile 
conditions at a concentration of 2% w/v, and purified by filtration at 0.2µm.  Small 
aliquots (280µl) of filtered alginate were loaded into a 3cc syringe and attached to a 
syringe driver.  A volume of 30ml of 0.15M calcium chloride (CaCl2) (Sigma-Aldrich) 
was placed in a 50ml beaker below the syringe pump as an ionic gelling bath, leaving a 
needle to bath working distance of 7mm.  A high voltage generator was attached to the 
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needle tip (30cc blunt tip, Amazon Supply) with a ground placed in the CaCl2 solution.  A 
constant voltage was next set on the high voltage generator to pass a field of current 
through the needle tip attached to the syringe.  The syringe pump was started to push the 
filtered alginate solution through the needle tip and into the CaCl2 gelling bath.  As the 
extruded alginate was pushed by the syringe pump it passed through the positively 
charged needle into the negatively charged CaCl2 gelling bath, creating spherical 
microcapsules. To test changes in microcapsule diameter, the voltage generator was set at 
voltages of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, and 6.0kV in individual tests, while flow rate 
(60mm/hr) and pH (7.4) were held constant during synthesis.  These experiments were 
repeated with (1.5kV) and without (0kV) the presence of an initial voltage being applied 
to the needle by the voltage generator prior to the start of the syringe pump.  This was 
done to see if any changes in microcapsule size resulted from the change.  Microcapsules 
were synthesized with and without the voltage set prior to starting the syringe pump, but 
voltage remained constant throughout the extrusion process once started.  Subsequent 
experiments to determine changes in microcapsule diameter were done using changes in 
flow rate (15mm/hr, 30mm/hr, 45mm/hr, and 60mm/hr) while voltage (4.0kV) and the 
presence of a starting voltage (1.5kV) were held constant.   
Alginate-poly-l-lysine (A-PLL) and alginate-poly-l-ornithine (A-PLO) 
microcapsules were produced by a 1 step method as a means to circumvent rapid 
diffusion and loss of peptide in initial time points that occur by multi-step methods of 
synthesis.  The initial method of 2% alginate preparation and instrument setup was 
repeated as described above. Polymer solutions of either poly-l-lysine (Alfa Aesar L-
lysine monohydrate 98%) or poly-l-ornithine (Alfa Aesar L-ornithine hydrochloride 
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99%) were mixed at a 0.5% w/v in 0.15M CaCl2.  A 0.5% w/v concentration for both 
polymers was selected based on preliminary results allowing dissolution of the material 
and ease in buffering to desired pH values.  The pH was buffered accordingly using 0.1M 
HEPES, 0.1M hydrochloric acid (HCL), or 0.1M sodium hydroxide (NaOH).  Polymer 
solutions were made at pH values either acidic (4.3) or biologically stable (7.4) for use 
during release studies.  Synthesized 2% alginate microcapsules were extruded into a 
polymer/0.15M CaCl2 bath and allowed to gel 12 minutes.  Microcapsules were removed 
from the gelling bath post-synthesis and rinsed in sterile deionized water, followed by 
examination of morphology by SEM and AFM.   
Microencapsulation and Release Profile of αCT1 Peptide 
Release profiles of αCT1 were studied over 48 hrs from alginate microcapsules 
extruded into CaCl2 solutions with pH values of 4.3, 7.4, or 9.3. In addition release 
profiles from poly-l-lysine and poly-l-ornithine coated capsules were studied using the 
same set of solution pH values.  Lowering the pH to a value opposite in scale to the 
isoelectric point (pI) value (theoretical 11.47) of αCT1 is thought to help slow the release 
rate by charge repulsion between the peptide and the external gelling solution.  The 
literature suggests potential methods of controlling release through changes in many 
parameters such as pH, polymeric coatings, changes in peptide concentration, addition of 
secondary ions or chemicals, and drying of capsules post synthesis (Gray et al 1988, 
Dashevsky 1998, Gombotz et al 1998, Vandenberg et al 2001, Tama et al 2011).  This 
data is not representative of the αCT1 peptide size and high isoelectric point (11.47 vs. 
BSA 4.7). The most similar cited release data to αCT1 is insulin (5.8 kDa).  In our studies 
we have elected to study release in alginate alone, alginate with polymer coating, and a 
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combination of both with variation in pH of the gelling solutions to characterize changes 
in αCT1 release.  
For these experiments, extrusion parameters were kept constant at 6.0kV, 0kV 
initial voltage, and a flow rate of 60mm/hr in all tests.  Previous published studies found a 
total αCT1 peptide concentration between 100-200µM created a therapeutic range 
(Ghatnekar et al 2009).  Therefore initial peptide concentration was kept constant at 
200µM.  Alginate concentration was also kept constant at 2%, while the polymer/CaCl2 
bath was synthesized at 0.5%polymer/0.15M CaCl2 as previously listed.  Initially, 
microcapsules were created using these parameters to show the effect of change from 
neutral pH solutions (7.2) to acidic (4.3) using 2% alginate without polymer coating.  
Tests were performed to show the effect of addition of both 0.5% A-PLL and A-PLO 
microcapsules to acidic pH solutions (pH 4.3).  An additional set of release profiles, 
conducted on microcapsules synthesized at 6.0kV, 60mm/hr, pH 7.4, were performed to 
examine the effects of loading concentration, comparing the 200µM concentration (used 
here in the pH and polymer coating tests) with a doubled 400µM amount. Post synthesis, 
microcapsules were rinsed in deionized water to remove excess gelling solution.  The 
capsules were then re-covered in 0.5mL deionized water, with time points taken over 48 
hours.  Early time points of 1, 2, 4, 6, and 8hrs were taken to account for early burst 
release of peptide from the microcapsules, with successive measurements taken at 24 and 
48hrs respectively.  Analysis of peptide concentration was performed using a Micro BCA 
protein assay kit (Thermo Scientific) with αCT1 replacing BSA for our standard curve.  
Additional standard curves using BSA were run against the αCT1 to establish any 
variations in linearity and changes in concentrations between the different molecular 
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weight protein and peptide used in the standards.  All tests were run on a BioTek Synergy 
2 spectrophotometer and performed in triplicate.  Statistics were compiled using the 
GraphPad Prism program with analysis using the student’s t-test program.   
Ultraviolet Crosslinking Attachment to Biomaterials   
An efficient and fast method of attachment of microcapsules to implanted 
materials was sought by ultraviolet (UV) crosslinking.  Microcapsules were attached to 
silicone, collagen, and PWAS sensor biomaterials exhibiting different material properties 
to determine the rate of attachment and overall area of coverage on the material surface.  
Flat 2.5% collagen cut into 1cm
2
 strips was coated by pipetting 30µl of empty 200µm 
alginate microcapsules onto the surface.  This volume of capsules was chosen to achieve 
complete initial coverage of the collagen surface.  The microcapsules were allowed to 
settle on the collagen surface and then UV crosslinked at one of four UV powers (6300, 
8000, 9000, 9999 µJ x100) using a Stratagene UV Stratalinker 1800.  Previous work 
using collagen tube samples indicated a UV power of 6300 µJ x100 was the minimum 
value necessary for crosslinking.  Therefore this value was used as a baseline starting 
point with three other representative values up to 9999 (maximum instrument value) as 
test points.  Increasing UV power was expected to create a hardening of the materials and 
therefore stronger bonding of the microcapsules to the biomaterials.  After UV 
crosslinking, the samples were then rinsed in deionized water to remove unattached 
capsules after one of two determined stop points: 0.5 or 24hrs.  These time points were 
selected to give an almost immediate short term point and long term point to compare the 
effects of drying on total attachment. Similar attachment tests were performed on 
piezioelectric wafer active sensors (PWAS) and small (1cm
2
) silicone discs to evaluate 
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coverage ability of UV crosslinking with the microcapsules on multiple implantable 
biomaterials for future in vivo experiments.  Electromechanical impedance is measured 
by the PWAS sensor as a means of evaluating in vivo reactions to implants (Giurgiutiu et 
al, 2004, Bender et al, 2006).  On both the PWAS sensors and silicone discs, a coat of 
100µl of 0.7% methylcellulose was applied to the surface for attachment prior to 
microcapsule placement.  Both of the later materials received 80µl of ~200µm empty 
microcapsules using the identical UV powers and time parameters tested on the collagen 
strips.  The difference in volumes of microcapsules applied to the silicone and PWAS 
sensors (80µl vs. 30µl) compared to the collagen is based on differences in the sample 
biomaterial sizes and the maintenance of complete surface coverage with microcapsules 
before UV crosslinking. These volumes were found to provide saturation of the materials 
surface with microcapsules prior to UV crosslinking. Analysis and images were obtained 
using a Zeiss Lumar V12 fluorescent microscope with Axiovision Release 4.9.2 software 
and a Zeiss Axiovert 135 phase contrast microscope with Axiovision Release 4.5 
software.  Statistical analysis was performed using the GraphPad Prism program 
analyzing an unpaired student’s t-test to determine significance.     
SEM Of UV Crosslinked Microcapsules 
Microcapsules were created at a diameter of 200µm with an encapsulated αCT1 
peptide concentration of 100µM using 2% sodium alginate as described above.  SEM was 
performed to characterize surface morphology and UV crosslinking effects on these 
capsules.  Microcapsules were prepared for SEM in two ways.  The first method involved 
preparation of microcapsules by UV crosslinking at 9000µJ x 100 twice to 0.7% 
methylcellulose coated glass coverslips.  This was done to match our protocol for surface 
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attachment to biomaterials previously listed in the UV crosslinking section.  A 24hr 
incubation period at 4°C was allowed, followed by air drying under laminar flow for 
2hrs.  The microcapsules were then critical point dried (Tousimis Samdri-PVT-3B) and 
gold sputter coated (Cressington 108 Auto/SE) for 3 minutes.  
The second method of preparation, performed to better view surface morphology 
without UV crosslinking, was carried out based on a modified protocol using the 
osmium-tannic acid-osmium method (OTO) (Murphy 1980).  Loose microcapsules were 
initially placed in a 0.1M Na Cacodylate, 3mM CaCl2, pH 7.2 buffer followed by a 
buffered fix of 2% paraformaldehyde, 2% glutaraldehyde, and 0.1% ruthenium red.  The 
microcapsules were next rinsed in 0.9% saline and placed in a secondary buffered fix 
consisting of 1% osmium tetroxide and 0.1% ruthenium red.  Next the samples were 
rinsed in 0.9% saline and placed in a series of alternating buffered fixatives containing 
either 1% tannic acid in 1% glutaraldehyde or 1% osmium tetroxide.  Rinses in these 
buffered fixatives were repeated 8 times at 20 minutes each with rinsing in 0.9% saline in 
between steps.  The microcapsules were finally rinsed with 0.9% saline to remove any 
buffer, dehydrated in a series of ethanol baths, critical point dried, and gold sputter 
coated.  SEM images were taken using a JEOL JSM-6300 SEM at 10kV.     
AFM of UV Crosslinked Microcapsules 
Analysis of microcapsule attachment to the implant materials and material 
structure was performed using AFM.  Glass coverslips were coated with 0.7% 
methylcellulose followed by representative samples (4.5kV or 6.0kV total voltage, 0kV 
initial voltage, and 60mm/hr flow rate) of 2% alginate microcapsules.  The microcapsules 
were UV crosslinked at 9000uJ x100 twice and incubated at 4°C for 24hrs prior to AFM 
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analysis.  The samples were run on an Asylum MFP-3D Series AFM instrument (Asylum 
Research), measuring relative adhesive forces and microcapsule stiffness according to 
previously a published protocol (Norris et al 2008).  Prior to analysis, the coverslips were 
attached to a glass microscope slide and equilibrated in the isolation chamber on the 
AFM stage for 5 minutes.  The laser was adjusted on the silicon nitride coated cantilever 
with a diving-board tip at 0.01N/m constant force (Asylum Research) to achieve 
maximum signal through alignment of the laser. Once aligned, the tip was brought into 
contact with the microcapsules using the AFM software, (Asylum IGORPro). Once in 
contact, an image of the scan area was taken which allowed a view of the sample and its 
features.  The initial scan taken was a 20µm x 20µm area and subsequent smaller scans 
were performed down to a 2µm x 2µm area.   From the chosen 2µm square area, we 
randomly selected 3-4 regions of interest to sample, selecting both peaks and valleys. 
These tips have a radius of curvature of less than 20nm. To obtain stiffness, the AFM was 
used in the “indentation mode”.  This data is converted through the program into either 
force-distance curves or indentation-distance curves.  The force distance curve was taken 
at this point by allowing the tip to approach the surface and retract, in quick pulses; this 
then relayed the static deflection of the tip on the surface. An average of 6 independent 
spots had a force distance curve performed on them. These were then averaged and 
normalized against the glass slide surface from which the force distance curve was 
generated. The result was a plot with two averaged curves, one for the approach and one 
for the retraction demonstrating pico-Newton forces along the nanometer scale of 
approach and retraction. In order to corroborate that the data was reliable, the curves 




2.4.1 Parametric Microcapsule Analysis 
Electrospray microencapsulation was performed as a comparative set of tests to 
establish the parameters necessary to produce a specific diameter of microcapsule.  In this 
proof of concept design, microcapsules were synthesized in a specific working range of 
voltages while examining the changes in microcapsule diameter with and without the 
addition of a starting voltage.  Further comparisons were made using the same working 
range of voltages, while examining the effect on diameter with changing flow rate.  A 
range of voltages between 2.5kV-6.0kV, a starting voltage of either 0kV or 1.5kV, and a 
series of flow rates (15mm/hr, 30mm/hr, 45mm/hr, and 60mm/hr) are used here as 
parameters.   
Figure 2.1.1 shows the results of the parametric design.  Figure 2.1A provides a 
graphical representation of the average microcapsule diameters in the 2.5-6.0kV working 
range under the two initial voltage conditions of 0kV or 1.5kV with the attached table 
below showing exact measurements with standard error.   Flow rate was kept constant at 
60mm/hr for all samples in figure 2.1.  Each point corresponds to the average 
microcapsule diameter of 25 representative capsules. A direct relationship between the 
total voltage and microcapsule diameter size was observed with a constant flow rate. 
Using a starting voltage of 0Kv and total voltage of 2.5Kv produced microcapsules with a 
diameter of 1383.1±12.5µm. When we changed our initial voltage to 1.5Kv we again saw 
a direct dependency between the total voltage and the microcapsule diameter. Similar to 
the results shown using a 0Kv starting voltage, a 2.5Kv total voltage produced 
microcapsules with diameters of 1259.8±7.9µm, which shrunk to 173.0±1.7µm when the 
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total voltage was increased to 6.0Kv. When individual total voltages were compared 
between the 0kV or 1.5kV starting voltages, no significant differences were seen 
(p<0.05). Both starting voltages had microcapsules that were larger and smaller at 
identical total voltage (figure 2.1A table).  Summarizing results, an overall decrease in 
diameter was seen when the initial voltage was changed from 0kV to 1.5kV at total 
working voltage points of 2.5kV (8.91% decrease), 3.5kV (25.92%), 4.0kV (3.29%), and 
4.5kV (14.38%). (Figure 2.1)  Similarly, an increase in microcapsule diameter between 
0kV and 1.5kV initial voltage was seen at 3.0kV (2.7% increase), 5.0kV (15.04%), and 
6.0kV (8.19%).   The lack of a consistent pattern of increase or decrease in microcapsule 
size and the results of the statistical analysis (p>0.05) indicated changes in starting 
voltage between 0kV and 1.5kV are not a significant parameter in changing microcapsule 
diameter. Overall our results confirm the presence of size variability in using the 
electrospray method.   
Examples of images of our synthesized microcapsules are seen in Figures 2.1 B, 
C, and D.  Figure 2.1B shows microcapsules extruded at 4.0kV, with a starting voltage of 
0kV and a continuous flow rate of 60mm/hr.  Similarly, Figures 2.1C and 2.1D show 
microcapsules synthesized at 4.5kV and 6.0kV with a 0kV starting voltage and 60mm/hr 
flow rate, respectively. 
Previous reports suggest that changes in flow rate are a determining factor in 
microcapsule diameter during synthesis (Chakraborty et al 2009, Zhang et al 2009).  We 
set out to determine whether changing the flow rate would have an effect on the 
variability of microcapsule size. Holding total voltage (4.0kV) and starting voltage 
(1.5kV) constant, we tested flow rates of 15mm/hr, 30mm/hr, 45mm/hr and 60mm/hr. 
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Microcapsules made at each of these flow rates showed an average change in diameter of 
<20µm when the overall voltage, initial voltage, and alginate concentration were held 
constant. (results not shown)  Using a one way ANOVA test with Gaussian 
approximation a p>0.05 was seen, indicating no significant changes in microcapsule 
diameters when flow rate was changed.  Taken together these data suggest that total 
voltage, rather than flow rate drove microcapsule diameter.  As a result, the remaining 
experiments in this paper used a constant flow rate of 60mm/hr in the microcapsule 
synthesis experiments.  Finally, these data indicate that a voltage of at least 3.0kV is 
necessary to overcome the surface tension of the alginate as it is extruded at this needle’s 
working distance, with values above 3.5kV and less than 6.5kV required to produce 












Figure 2.1 Results of the parametric study of sodium alginate microcapsules.  (A) 2% 
sodium alginate microcapsules were made with seven different voltages between 2.5kV-
6.0kV using a constant starting voltage of 1.5kV. These results are shown in the graph 
indicated by stars, with average diameters listed for each parameter in the table below the 
graph.  The study was repeated with the same total voltages and a constant voltage of 
0kV. These results are represented by squares, with average capsule diameters in the 
table below. (B) Phase contrast image of microcapsules created at 4.0kV, 0kV starting 
voltage, and 60mm/hr. (C) Phase contrast image of microcapsules created at 4.5kV, 0kV 
starting voltage, and 60mm/hr. (D) Phase contrast image of microcapsules created at 








2.4.2 Loading and Release of αCT1 From Alginate and Polymer Coated 
Microcapsules  
To characterize our microcapsules as a potential drug delivery vehicle, a series of 
release profile experiments were conducted.  Of interest was the controlled release of 
αCT1 for extended use in future regenerative medicine studies.  Our desired outcome was 
to obtain a continuous release over a 24+ hr period. In conducting these release 
experiments, we examined the effect of pH of the gelling bath solution first with sodium 
alginate microcapsules, followed by the effects of both pH of the gelling bath with 
addition of either PLL or PLO polymer coating to the alginate capsules. Additional tests 
were performed varying the ratio of αCT1 to sodium alginate prior to application.  These 
results are presented in Appendix A.1.   
Initially, loading efficiency experiments were conducted on four samples using 
6.0kV total voltage, 0kV starting voltage, 60mm/hr flow rate, an αCT1 concentration of 
200µM, and a 2% alginate solution.  Measurements using a micro BCA protein assay 
indicated a loading efficiency of 72.53 ± 1.59%.  Two identically synthesized sets of 
microcapsules, one at a concentration of 200µM and one at 400µM, were analyzed for 
release.  The results, shown in figure 2.2, indicated a rapid initial burst of αCT1 prior to 
the initial 1hr time point when loading with 400µM. As such, only 11.22µM was 
measured over the initial 4hrs vs 27.73µM when loading with 200µM. Using the same 
controlled parameters, we next synthesized 2% alginate capsules at a 200µM peptide 
concentration and measured the release over 48hrs with the pH of the calcium chloride 
gelling bath at either 4.3 or 7.2.  Figure 2.3A shows the 48hr release profile of 2% 
alginate microcapsules extruded into an acidic 4.3 calcium chloride bath while 2.3B 
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shows capsules extruded into a neutral 7.2 pH bath, and 2.3C extruded into a basic 9.3 pH 
bath.  The insets on each graph show the first five hours of release for better appreciation 
of the rapid release of the peptide. Average results for each time point are presented in 
the table in Figure 2.3.  Previous reports have suggested that an acidic pH acts to reduce 
the pore size of the microcapsules and therefore slows peptide release (Dashevsky 1998, 
Vandenberg et al 2001).  When microcapsules were extruded into an acidic environment, 
an overall lower initial release of peptide in the first hour (21.93µM vs 11.67µM) was 
observed (Figure 2.3 table).  However, the acidic environment allowed for an extended 
release over the first four hours.  In comparison, a larger total amount of peptide is 
released over the 48hr period at a neutral pH vs. acidic pH, but by only 5.7µM.  The 
lowest total release over the first four hours was seen in the basic 9.3 pH environment. 
The biological impact of this difference in peptide is unknown at this time and must be 
examined in order to determine significance.  Based on these results, addition of an acidic 
environment at synthesis slows release of the αCT1 peptide and thus extends the profile 
timeline.   
We next tested whether a change in pH of the alginate solution (pH 4.3 vs pH 7.2) 
prior to synthesis with a neutral buffered gelling bath (pH 7.2) would produce changes to 
initial burst or extended release kinetics over a 48hr period.  No significant changes 
(p>0.05 comparing identical time points between pH 4.3 and 7.2) to either the initial 
release of the peptide or extended release were observed (Data not shown).    
We then set out to determine if coating the alginate microcapsules could enhance 
peptide release. The results in figure 2.4 show a comparison of release over 48hrs in three 
microcapsule types at a pH of 4.3 using the same parameters and peptide concentration as 
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described above.  In each case the alginate solution was mixed at a 2% concentration 
while the additional polymer coating solution was made at 0.5% w/v.  Figure 2.4A 
presents release data over 48hrs from 2% alginate capsules without additional polymer 
coating at a pH of 4.3.  Figure 2.4B shows the A-PLL (poly-l-lysine) polymer coated 
microcapsules release data over 48hrs at a pH of 4.3.  Figure 2.4C similarly shows the 
release data of A-PLO (poly-l-ornithine) polymer coated capsules at a pH of 4.3.  The 
Figure 2.4 table shows the concentration values of peptide release at each time point for 
each of the three capsule types.  Total peptide released from the A-PLL capsules was 
44.68 ± 2.99µM vs. 113.99 ± 42.85µM for the A-PLO capsules at a pH of 4.3.  This 
represents a 155.13% increase in released peptide through the change in polymer type at 
equal polymeric concentrations.  In addition, the total peptide concentration released was 
284.58% (84.35µM difference) greater from the A-PLO coated capsules compared to the 
uncoated 2% alginate capsules at the same pH.  The peptide release seen in the A-PLO 
capsules had higher standard error values in hours 1-4 in these tests, which was greater 
than values found in the other two capsule types in figure 2.4.  Calculating the maximum 
high range of the A-PLL capsules in comparison to the low range of the A-PLO capsules 
resulted in a 49.23% (23.47µM) change in total peptide release between the two capsule 
types.  However, statistical analysis of hours 1-4 on the A-PLO vs A-PLL and A-PLO vs 
2% alginate without polymer at an acidic pH resulted in significance in both cases (p< 
0.05).   
When taken together, these data lead us to conclude the addition of polymer 
coating in this one step method significantly increases the total amount of peptide we are 
able to effectively release and deliver over a 48hr period.  More specifically we saw 
32 
 
another significant increase in peptide release in using a PLO coating at a 0.5% w/v 
concentration.  By combining the changes in both pH and polymer coating, a more 










Figure 2.2 Release profiles examining change in release with differing initial loading of 
αCT1 over 48hrs. Profiles of both 200µM (top) and 400µM (bottom) loaded 
microcapsules synthesized with no starting voltage, 6.0kV total voltage, and 60mm/hr 





Figure 2.3 Release profile comparison of 2% alginate microcapsules synthesized and 
gelled in a 0.15M CaCl2 bath at a pH of 7 vs. identical capsules synthesized at a pH of 4.3 
and 9.3.  All microcapsules were made with an αCT1 concentration of 200µM, no 
starting voltage, a flow rate of 60 mm/hr, and a total voltage of 6.0kV. (A) 2% alginate 
microcapsule release profile with synthesis in a gelling bath at a pH of 7. (B) 2% alginate 
microcapsule release profile with synthesis in a gelling bath at a pH of 4.3. (C) 2% 
alginate microcapsule release profile with synthesis in a gelling bath at a pH of 9.3. 
Below is a table of average measured αCT1 concentrations over 48 hrs at each time point.  
Measurements are the result of three separate tests and evaluation using a Micro BCA 





Figure 2.4 Release profiles comparing 2% alginate microcapsules synthesized in a 
0.15M CaCl2 gelling bath at a pH of 4.3 against both A-PLL and A-PLO microcapsules 
synthesized at an identical pH of 4.3.  Additional images of 2% alginate, A-PLL, and A-
PLO microcapsules synthesized at a pH of 4.3, total voltage of 3.5kV, and flow rate of 60 
mm/hr are shown beside each corresponding graph.  Below A, B, and C is a table listing 
exact values of peptide measured at each time point with standard error. (A) 2% alginate 
microcapsule release profile with synthesis in a gelling bath at a pH of 4.3. (B) A-PLL 
microcapsule release profile. (C) A-PLO microcapsule release profile. 
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2.4.3 UV Attachment of Alginate Microcapsules to Biomaterials 
 
We sought to use UV crosslinking of our microcapsules as a means of attachment 
to specific implantable biomaterials of interest.  Here we show attachment to three 
different biomaterials; 2.5% collagen, silicone discs, and PWAS sensors.  UV 
crosslinking provides a means of stabilization of the alginate/polymer materials while 
also acting as a non-interfering and biocompatible method.   
Four differing UV powers (6300, 8000, 9000, and 9999µJ x100) were chosen for 
use.  In addition, we also varied the time after UV crosslinking the capsules were on the 
substrates prior to testing to determine if any significance existed.  Two time points were 
chosen; one of a short duration (0.5hrs) and a second longer duration (24hrs) to examine 
the effect of drying time on attachment.  Microcapsules were synthesized at a 2% alginate 
concentration and diameter of 200µm, followed by coating on the biomaterial surface.  
Samples were then crosslinked at the set powers following placement of the 
microcapsules to the biomaterial.  Incubation post crosslinking at both the short and long 
time points was carried out at 4°C before rinsing with deionized water three times to 
remove unattached capsules.  Attached capsules were imaged and the total area covered 
by microcapsules was marked and measured.  Figure 2.5A shows a representative sample 
of 2.5% collagen coated with 2% alginate microcapsules post UV crosslinking at 9999µJ 
x 100.  Similarly, figure 2.5B shows an image of a PWAS sensor coated and UV 
crosslinked at 9000µJ x 100.  Figure 2.5C shows an image of a silicone disc coated in 
microcapsules post UV crosslinking at 8000µJ x 100. 
The results shown in the corresponding graphs indicate the percent area covered 
by microcapsules on each material surface (Figure 2.5D (2.5% collagen), 2.5E (PWAS 
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sensor), and 2.5F (silicone disc)).  Results in each graph indicate average area of 
coverage based on four separate trials.  Analysis of the data show the longer (24hr) 
incubation time drastically increased the area of microcapsule attachment on all three 
materials.  The results also showed that the greatest total surface coverage for both the 
collagen (40.17% ± 19.10) and PWAS sensors (39.03% ± 6.72) was achieved when UV 
crosslinking was done at a power of 9000µJ x 100. In contrast, the silicone attachment 
indicated the highest area of microcapsule attachment occurred with a UV power of 
9999µJ x100 (22% ± 9.72), with the results of 8000 (17% ± 7.03) and 9000µJ x100 (21% 
± 2.23) producing similar results at 24hrs.  In all instances using the UV crosslinking 
method, we observed that a total surface area of coverage was never greater than 45% 
following rinsing. To maintain microcapsule morphology and prevention of any possible 
changes in peptide release from the microcapsules, a small amount of supernatant was 
left on the capsules to insure integrity. This volume was minimal but necessary for 
integrity to be preserved.  The amount of supernatant used was estimated to be enough to 
slightly cover the capsules.  In total, for future applications, UV crosslinking was shown 
to provide a viable method of attachment and delivery of microcapsules with maintained 
morphology, but limitations in total coverage of surface area of the materials was 





Figure 2.5 UV crosslinking of microcapsules to biomaterials (A) Post rinse 
microcapsules shown attached to 2.5% collagen after 24hrs incubation and UV 
crosslinking at 9999µJ x100. (B) Post rinse microcapsules shown attached to a PWAS 
sensor after 24hrs incubation and UV crosslinking at 9000µJ x100. (C) Post rinse 
microcapsules shown attached to silicone after 24hrs incubation and UV crosslinking at 
8000µJ x100. (D) Graph illustrating average microcapsule attachment to 2.5% collagen at 
4 UV powers and either a 0.5hr or 24hr incubation. (E) Average microcapsule attachment 
to PWAS sensors at 4 UV powers and either a 0.5hr or 24hr incubation. (F) Average 
microcapsule attachment to 1cm
2




2.4.4 The Affect of UV Crosslinking on Microcapsule Integrity and Morphology 
To investigate the possible effects of UV crosslinking on microcapsule 
morphology, samples of microcapsules were analyzed by SEM imaging.  Maintenance of 
spherical morphology and pore structure is critical to achieve proper release of peptide 
from the microcapsules in the same manner shown in our release studies.  Samples of 
200µm 2% alginate microcapsules were placed on glass coverslips coated with 0.7% 
methylcellulose, UV crosslinked at 9000µJ x100 twice, then incubated for 24hrs at 4°C.  
A UV power of 9000µJ was selected based on the perceived effectiveness shown at this 
power in the UV crosslinking attachment data previously shown.  Post incubation the 
microcapsules were dried and processed for SEM.  Figures 2.6A (200X), 2.6B (2,500X), 
2.6C (700X) and 2.6D (700X) show representative examples of these microcapsules at 
the indicated magnifications.  Upon examination of these capsules, we observed little 
negative effect on morphology due to UV crosslinking damage.  Figure 2.6A shows 
possible clumping and lateral bonding of the microcapsules to one another, which may 
have an effect on the overall surface area available.  This could lead to variations in the 
release rate of the microcapsules.  Overall the microcapsules maintained a spherical 
morphology upon processing and UV crosslinking.  In addition, no surface damage was 
observed when examined at higher power (Fig 2.6B). These data further support the idea 





Figure 2.6 SEM images of αCT1 containing microcapsules synthesized at voltages of 
4.5kV and 6.0kV using 2% sodium alginate. (A) Sample image of a microcapsule 
synthesized at 4.5kV without UV crosslinking and a 550X magnification. (B) 550X 
magnification, 10kV image of 6.0kV synthesized microcapsule with UV crosslinking at 
9000µJ twice. (C) 550X magnification, 10kVmicrocapsule synthesized at 4.5kV with UV 
crosslinking at 9000µJ twice. (D) 700X magnification, 10kVmicrocapsule synthesized at 










2.4.5 Assessment of the Microcapsule Mechanical Properties Using AFM 
Finally, we sought to determine if there were differences in the mechanical 
properties of the microcapsules at the various conditions used to extrude the 
microcapsules and upon UV crosslinking. To that end, AFM was used to characterize the 
mechanical properties (e.g. stiffness) of the UV crosslinked microcapsules.  AFM can 
measure the stiffness and rigidity of the microcapsule while also examining the 
morphology in a similar manner as we did with SEM.   
Two representative sizes of 2% alginate microcapsules were selected for 
examination; 260µm (4.5kV total voltage, 0kV starting voltage, and 60mm/hr flow rate) 
and 160µm (6.0kV total voltage, 0kV starting voltage, and 60mm/hr flow rate).  Each 
sample was first placed on 0.7% methylcellulose coated glass coverslips then UV 
crosslinked at 9000µJ x 100 as described above in the SEM procedure.  Glass coverslips 
were used in place of the biomaterials previously listed to compensate for rigidity and 
size needs on the AFM.  Figure 2.7 shows the results of the AFM testing of our 
microcapsules.  Figure 2.7B (4.5kV) and 2.7D (6.0kV) represent the results of AFM 
scanning of microcapsules without UV crosslinking.  Figures 2.7A (4.5kV) and 2.7C 
(6.0kV) contain the results of scanning on UV crosslinked microcapsules.  Figure 2.7A, 
2.7B, 2.7C, and 2.7D each contain the results of the scans in the form of a heat map (left) 
and a force map (right).  Consistency scans were performed on each capsule type prior to 
analysis to check for consistency in microcapsule morphology and curvature (not shown).  
When a comparison of the force maps for both A and C is done, a dramatic variation in 
material property is observed.  The samples scanned prior to UV crosslinking showed 
little variation in adhesion forces with median forces at 54.26pN for 6.0kV and 90.27pN 
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for 4.5kV extraction.  However, the samples scanned after UV crosslinking indicated an 
order of magnitude change in overall adhesion and a 10 fold change in adhesion forces 
between the microcapsule samples (median values of 100nN for 6.0kV vs. 7.7 nN for 
4.5kV).  The UV crosslinking does increase the stiffness of the microcapsules, as 
expected, however, the AFM data suggests the UV crosslinked microcapsule structures 
experienced a change in stiffness that may be attributed to other factors than strictly UV 
power.  Possibilities include microcapsule size and density of dispersion on the material 
surface.  The AFM data also allows us to characterize the microcapsule shape post UV 






Figure 2.7 AFM characterizing two microcapsule samples; 4.5kV total voltage and 
6.0kV total voltage, which were either UV crosslinked to glass coverslips prior to 
analysis at 9000μJ x100 or left untreated and analyzed. Data is obtained from 20μm x 
20μm scan areas on the coverslips where microcapsules were identified with the area then 
narrowed to 2μm
2
 areas. Three areas of interest with peaks and valleys were then scanned 
on each sample. An average of 6 independent spots had a force distance curve performed 
on them. (A) 4.5kV microcapsules with UV crosslinking resulting heat map (left) and 
force map (right). (B) Data obtained for non-UV crosslinked 4.5kV extruded 
microcapsules. (C) 6.0kV extruded microcapsules with UV crosslinking. (D) 6.0kV non-




The creation of consistent, reliable and controlled microcapsules is a desire in the 
drug delivery field and was examined in this study. The data presented here describes the 
parameters necessary to produce such microcapsules with controlled size and 
morphology.  Our data support numerous studies that have documented the inherent 
variability present in using the electrospray method of microencapsulation.  In addition 
we set out to determine the effect of using a small, low molecular weight peptide on the 
release profiles of standard and modified sodium alginate microcapsules.  The first 
parameter we examined was the addition or removal of an initial electric field established 
slightly below the working range of synthesis during encapsulation. Voltage applications 
for electrohydrodynamic techniques, such as the electrospray method, are subject to 
decreasing microcapsule diameter with increasing voltage strength, up to a certain point.  
A voltage below 1.2kV/cm creates reduced microcapsule diameters; however voltages 
above this value fail to increase microcapsule diameter (Katti et al. 2004).  In our studies 
we determined that using voltages higher than 6.0kV on our instrument resulted in little 
change in microcapsule diameter. Therefore, microcapsules synthesized at voltages 
higher than those previously listed were omitted (data not shown). 
Establishing a release profile for low molecular weight peptides has proven 
difficult when working with microcapsules due to the reliance on simple diffusion from 
the spheres.  As a result, many groups have sought to create methods to control this 
release by altering extrusion parameters or inclusion of additional materials meant to 
interfere with the pathway of diffusion.  Our study has shown changes created by 
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encapsulation of a small, low molecular weight peptide in contrast to other larger proteins 
such as BSA.     
In addition to differences in molecular weight, the photoelectric points of the 
encapsulated peptide appear to have effects on diffusion from the microcapsule.  A 
peptide or protein with a low pI, such as that seen in BSA (4.7), diffuses faster in a 
neutral environment. In contrast, the αCT1 peptide has a much higher (theoretical 11.47) 
pI value and thus lowering the pH below this number is thought to help decrease release 
rate.  Based on our results, when comparing a neutral pH environment with an acidic pH 
environment, there was a reduced level of peptide diffusion.  By altering the pH the 
peptide was shown to have a lower initial burst and more evenly dispersed release over 
the first four hours.  Over the first four hours the average difference in total peptide 
released differed by <5 µM at each time point.  When compared to typical initial burst 
measurements the total peptide released in the first four hours shows sustained diffusion 
using these parameters.  Other attempts to obtain modified diffusion have been made by 
the addition of polymer coating of microcapsules.  We chose to coat microcapsules using 
both PLL and PLO.  Again, we saw extended release in early (1-4hrs) time points similar 
to values shown using an acidic environment, but with increased peptide release over a 
longer duration of time (8hrs vs 4hrs).  Thus it appears that choosing a proper pH 
environment and polymer coating can be used to improve release duration of low 
molecular weight peptides.   
 In an attempt to attach and deliver microcapsules on biomaterials for 
implantation, we examined the use of UV crosslinking on the integrity of the extruded 
microcapsules.  UV attachment was performed on three biological materials; polymerized 
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collagen, silicone wafers, and PWAS sensors.  Two incubation periods were used for 
attachment of the microcapsules to the biomaterials, 0.5hrs and 24hrs at 4°C.   In each 
case an incubation time of 24hrs prior to rinsing produced the greatest coverage area of 
microcapsules.  In addition multiple UV powers were used to attach the microcapsules to 
the biomaterials, ranging from 6300, 8000, 9000, and 9999µJ X100.  Attachment of the 
microcapsules to the hydrophobic silicone disks showed the lowest total coverage area 
percentage of the three materials at 24hrs and 9000µJ, (17% vs ~40%) which was found 
to be the parameters of highest attachment in both collagen and PWAS sensors. 
Attachment to the silicone disks also had the most variability between the UV powers and 
different incubation times.  On the other hand, UV crosslinked microcapsules on both 
2.5% collagen and PWAS sensors produced total coated areas of 39-40%.  This level of 
coverage was achieved without addition of any outside adhesive agents or potentially 
interfering materials, which could elicit an inflammatory response or prove to be non-
biocompatible.   We feel that UV crosslinking may provide promise as an efficient 
microcapsule attachment method.  Further testing must be performed before UV 
crosslinking can be considered a significant advantage. 
 To begin this testing we sought to determine the effects of UV crosslinking on the 
biomechanical properties of the alginate microcapsules.  Both SEM and AFM analysis of 
our UV crosslinked microcapsules was performed.  No significant changes in overall 
morphology or microcapsule size were noted upon imaging of the UV crosslinked 
structures.  SEM images show consistency in round morphology with little structural 
damage after crosslinking.  AFM analysis showed that changing synthesis parameters 
(i.e. voltage) created a change in microcapsule stiffness after UV crosslinking.  Previous 
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studies using simulated models have evaluated AFM and finite element modeling values 
to assess the membrane elastic-plastic properties of microcapsules similarly (Wan, et al 
2002; Mercade-Prieto et al 2011).  Our preliminary AFM analysis demonstrated a 10 fold 
change in overall stiffness between 4.5kV and 6.0kV synthesized capsules.  Further AFM 
analysis of the microcapsules created at these voltages must be conducted to determine 
the significance of the change. Moreover further AFM analysis including polymer coated 
microcapsules must be completed.   
Finally, previous experiments using excisional skin wounds have been conducted 
using the topical application of the αCT1 peptide in vivo (Rhett et al 2008; Ghatnekar et 
al 2009).  In addition, several papers have been published using both nano and micro 
scale polymeric DDS systems synthesized using electrohydrodynamic methods for use 
with wound healing models with promising results (Zhao et al 2005; Rho et al 2006; Choi 
et al 2008).  Our data suggests that by appropriate modification and attachment, a 
controlled delivery may be obtained using these sodium alginate microcapsules for use 
with in vivo models.     
2.6 Conclusions 
Sodium alginate microcapsules provide a promising means of controlled delivery 
of biomaterials and drugs, including the αCT1 peptide.  Our study provides a 
characterization of this DDS, both in synthesis and pharmacokinetics capabilities.  
Furthermore, we have provided a new attachment method of delivery for coating of 
biomaterials with microcapsules for multiple in vivo circumstances.  Multiple 
microscopy techniques show that use of this method provides potential positive effects to 
the microcapsule functionality. 
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CHAPTER 3: APPLICATION OF THE αCT1 PEPTIDE BOTH DIRECTLY AND 
THROUGH CONTROLLED RELEASE IN A RAT CORNEAL INJURY MODEL 
3.1 Abstract 
The ability to safely and quickly close wounds and lacerations is an area of need 
in regenerative medicine, with implications toward healing a wide range of tissues and 
wounds.  Using an in vivo corneal injury model, our study applied the αCT1 peptide, 
capable of promotion of wound healing and epithelial regeneration. The αCT1 peptide is 
a 25 amino acid peptide from the C-terminus of connexin 43 (Cx43), modified to 
promote cellular uptake.  Previous studies applying αCT1 to excisional skin wounds in 
porcine models produced tissues having an overall reduced level of scar tissue and 
decreased healing time.  Rapid metabolism of αCT1 in previous work led to the 
investigation of extended release on wound healing rate used in this study. Here we 
delivered αCT1 both directly, in a concentrated pluronic solution, and in a sustained 
system, using polymeric alginate-poly-l-ornithine (A-PLO) microcapsules, previously 
characterized in chapter 2. Cell toxicity analysis showed minimal cell-loss with 
microcapsule treatment. Measurement of wound healing using histology and fluorescence 
microscopy indicated significant reduction in healing time of αCT1 microcapsule treated 
rat corneas compared with controls (49.92% decrease in wound area) at 24hrs.  RT-PCR 
analysis showed an initial up regulation followed by down regulation of the gene keratin-
19 (Krt19).  Zonnula occludin-1 (ZO-1) showed an opposite down regulation followed by 
an up regulation whereas Cx43 showed a biphasic response.  Inflammatory indexes
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demonstrated a reduction in the inflammation of corneas treated with αCT1 
microcapsules when compared with pluronic gel vehicle.  These results suggest αCT1, 
when applied in a sustained release system, acts as a beneficial wound healing treatment. 
3.2 Introduction   
The cornea is the nonvascular outermost layer of the eye.  Roughly five to six cells 
thick, the corneal epithelium accounts for 10% of the corneal thickness and blocks entry 
of materials into the eye, absorbs oxygen, and senses pain as a protective response.  The 
cornea acts as the entry point of light into the eye, and therefore, must remain unaltered to 
maintain proper vision and allow for the correct formation of an image on the retina.  
Issues such as trauma, opaque discoloration, and keratoconus (thinning) create the need 
for corneal replacement surgery, or keratoplasty, using donor tissue. The ability to heal 
native corneal tissue would alleviate side effects such as infection and keratoplasty as 
well as the need for donor tissue (Aomatsu et al, 2012; Fukuda et al, 2012; Grupcheva et 
al, 2012; Karamichos et al 2011; Lu et al, 2012; Shi et al, 2012; Shimmura et al, 2005; 
Trinkaus-Randall et al 1998; Yao et al, 2012). As previously detailed, corneal wound 
healing involves several complex overlapping processes involving keratocyte 
proliferation and migration, myofibroblast recruitment, inflammation induction and 
response, and epithelial regeneration. The steps of this process are known, but details of 
the signaling pathways are still unclear. In our research the Epithelial Mesenchymal 
transition (EMT) pathway was investigated to determine the relationship to corneal 
wound healing and the resulting reaction to αCT1 treatment, specifically here focusing on 
krt19. Preliminary data suggested a strong up regulation of krt19 in response to αCT1 in 
vitro. EMT is a biological method of cellular rearrangement and repair of damaged tissue 
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where immobile cells used for structural integrity and boundary formation may be 
mobilized to an area of need (Lee et al 2006). Once the EMT process is complete the 
mesenchymal cells convert back to epithelial cells in mesenchymal-epithelial transition.  
Typically the EMT process is tightly regulated by the body, as in embryogenesis 
(Radisky 2005).  The EMT process is not as well understood in the eye, with different 
opinions on the relationship with corneal wound healing.   
The αCT1 peptide is a biotinylated 25 amino acid sequence, comprised of a 16 amino 
acid antennapedia domain, connected to a 9 amino acid (RPRPDDLEI) sequence from 
the C-terminus of Cx43 (Rhett et al 2009, 2011). The cytoplasmic tight junction protein 
zonula occluden 1 (ZO-1) binds at its PDZ-2 domain with the DDLEI sequence of the 
Cx43 C-terminus end (Duffy et al, 2002).  Previously Barker et al (2002) found that 
intact ventricular myocardium exhibited a low level of ZO-1-Cx43 interaction.  This 
interaction may be disrupted, leading to changes in protein-protein interactions which 
affect formation of gap junctions. Connexins play a key role as mediators of both cell 
growth and death and function in immune response, hematopoiesis, and development of 
progenitor cells (Herve et al, 2004, Oviedo-Orta et al, 2004; Vinin et al, 2011).  Binding 
of the C-terminus of Cx43 to ZO-1 is believed to affect cellular communication and gap 
junction remodeling in wound healing (Soder et al, 2009).   αCT1 competitively inhibits 
this binding (Hunter et al, 2005; Soder et al, 2009), increases the rate of wound healing, 
and when applied to in vivo models reduced scar tissue formation in multiple wound 
healing models including cardiovascular injury, biomedical device implantation, and 
excisional skin wound models (Ghatnekar et al, 2009; O’Quinn et al, 2011; Soder et al, 
2009).  Barker et al also developed a control peptide with the active C-terminus 9 amino 
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acid sequence reversed while the inactive 16 amino acid antennapedia portion was left 
unchanged. While these results are promising αCT1 showed a rapid metabolism rate.  As 
a result we synthesized microcapsules capable of extending release of αCT1 over 48 hrs 
to determine to therapeutic potential.    
Microcapsule synthesis is accomplished using multiple methods, of which the 
electrospray method is used in this study. Electrospray microencapsulation uses a voltage 
differential between a positively charged syringe attached to a high voltage generator and 
a grounded material, such as a crosslinking gelling bath. A device to control flow rate, 
such as a syringe pump, passes a polymeric material through the voltage field, which 
overcomes the surface tension force to produce droplets of a specific size (Chakraborty et 
al, 2009; Enayati et al, 2011).  Sodium alginate is a widely used polymer based on its 
biocompatibility, semi-permeability, and low cost production (Hilborn et al, 2007; Orive 
et al, 2006; Tama et al, 2011; Wright et al, 2012; Zhang and He, 2009). In this study 
sodium alginate microcapsules serve as the base microencapsulation material with a 
single layer of 0.5% poly-l-ornithine coating added.   
3.3 Materials and Methods 
Surgical Creation of Corneal Wounds and Post-Surgical Treatment 
Male Sprague-Dawley rats (Harlan Laboratories) weighing 240-260 grams were 
used in this study.  All experiments were carried out in compliance with the Guide for the 
Care and Use of Laboratory Animals by the National Academy of Sciences and 
University of South Carolina Animal Resources Facility guidelines. Before and after 
surgery animals were housed two per cage with food and water given ad libitum.  Prior to 
surgery, rats were placed under using an anesthesia mixture of 60mg/kg Ketamine, 
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7.5mg/kg Xylazine, and 1mg/kg Acepromazine.  Two drops of a topical anesthetic, 
Alcaine (Alcon Canada, Mississauga, Canada) were applied to each eye.  Excess Alcaine 
was removed with a sterile ophthalmic sponge (Merocel, Beaver-Visitec International).  
A 5mm trephine was placed on the surface of the cornea and two drops of 20% isopropyl 
alcohol were placed on the cornea surface for exactly 30 seconds. Exposure to the alcohol 
solution created a loosened 5mm area of corneal epithelium where the trephine was 
placed.  Under a dissecting microscope, the 5mm area of damaged corneal epithelium 
was removed by gentle scraping, leaving the exposed stromal layer.  Once the epithelium 
was removed the cornea was rinsed with 1% saline and wiped with an ophthalmic sponge 
to remove any remaining loose epithelium.   
Post surgery, rats were placed into one of five time point groups spanning a one 
month period; 1 day, 3 days, 10 days, 21 days or 30 days.  These five time points were 
repeated for four separate treatments with a total of 100 rats used in the study (25 per 
treatment/5 per time point). At each time point a total of 10 eyes were used with identical 
treatment in both eyes of each rat to eliminate eye to eye cross contamination.  Treatment 
groups were comprised of two controls (pluronic gel alone and reverse sequence peptide) 
and two treatments with αCT1 peptide (direct application and diffusion from 
encapsulated αCT1 A-PLO microcapsules).  In order to ensure sustained delivery of 
peptide into the cornea, a pluronic gel carrier (Pluronic F-127, Sigma) was used at a 
concentration of 25% w/v.  The pluronic solution remains liquid at 4°C, but gels once in 
contact with the warm eye.  Control group rats received treatments of either 10µl 25% 
pluronic gel or 10µl of 150µM reverse peptide/25% pluronic gel.  Application of αCT1 
consisted of either 10µl 150µM αCT1/25% pluronic gel per eye or 150µM αCT1 
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Microcapsules/10µl 25% pluronic gel per eye with A-PLO microcapsules.  Each 
treatment was applied immediately after surgery (0 hrs), at 24 hrs, and at 72 hrs.  All rats 
were ethically sacrificed at the designated endpoints. 
Synthesis of αCT1 Loaded A-PLO Microcapsules 
Microcapsules were synthesized according to the protocol previously detailed in 
chapter 2. Sterile sodium alginate (Sigma-Aldrich catalog#A0682, high maluronic acid 
content, low viscosity) poly-l-ornithine (Alfa Aesar L-ornithine hydrochloride 99%) 
microcapsules were synthesized and release of αCT1 was measured.  All microcapsules 
were synthesized with a 2% alginate/0.5% PLO concentration and gelled in 0.15M 
calcium chloride (CaCl2) (Sigma-Aldrich) solution for 12 minutes.  The synthesis 
parameters were constant at a needle to working bath distance of 7mm, a voltage of 
6.0kV, and a flow rate of 60mm/hr.  Microcapsule solutions were buffered to pH 4.3 
using 0.1M HEPES and 0.1M hydrochloric acid (HCL). A-PLO microcapsules were 
loaded with αCT1 at an initial concentration of 200µM.  
Cytotoxicity Testing of Microcapsules  
Cytotoxicity of materials used for A-PLO microcapsule synthesis was tested using 
an XTT based In Vitro Toxicology Assay Kit (Sigma Aldrich) on rabbit lens epithelial 
cells (RLECs) according to manufacturer’s instructions.  A cellular optimization assay 




 cells per well to determine the 
linear range of XTT reaction in these cells.  Based on the results of these tests, 60,000 
cells per well were seeded onto a 96-well plate in media containing DMEM/1%FBS, 
50ug/mL Gentamycin, 0.5% Penicillin, and 0.1% Amphocyterin B for 24 hrs.  The cells 
were then treated with a mixture of media with 2% CaCl2, 150µM A-PLO microcapsules 
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pH 4.2, 150µM A-PLO microcapsules pH 7.2, 150µM αCT1, or 150µM 2% alginate 
microcapsules pH 7.2, followed with incubation for 24 hrs.  Cells treated with media 
alone served as a positive control, while cells treated with 2% Triton-X 100 (Sigma 
Aldrich) served as a negative control. After 24 hrs the cells were rinsed in media, and 
XTT was added to each well at a 0.33 mg/mL concentration diluted in cell culture 
medium with 8.3 µmol/L phenozene methyl sulfate (Sigma Aldrich). The cells were then 
incubated for 24 hrs and absorbance was read at 450nm using a BioTek Synergy 2 
spectrophotometer.  Results are the average of six repeats from separate cell isolations 
and are reported as a percentage of the positive control following background subtraction 
of media only wells.  Standard error and mean were analyzed and plotted using GraphPad 
Prism 5 software. 
Fluorescent Wound Imaging for the Evaluation of Wound Closure Rate  
To assess wound closure rates, 2µl drops of Fluress (fluorescein sodium and 
benoxinate hydrochloride, Akorn Incorporated) GFP labeled fluorescent dye were placed 
on the wounded cornea and allowed to cover the eye surface.  Excess dye was removed 
using a sterile ophthalmic sponge, leaving a thin coat attached to the corneal surface.  
Fluress coats the cornea and penetrates the injury site, but is rinsed from the intact 
cornea. This allows fluorescence visualization of differences in the topography in areas of 
tissue damage. Images were taken of the wound at 0 hrs (immediately post surgery), 1 
day, 3 days, 10 days, 21 days, and 30 days, using a Zeiss Lumar V12 fluorescence 
microscope with a 20X objective and 1.5X lens magnification. All images were taken 
immediately prior to application of treatments. Each wound site area was measured using 
Axiovision Release 4.8.2 software. The percent decrease in wound area was calculated 
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for each trial and treatment by comparing differences in wound area between initial and 
final measurements taken at each time point. Graphing and statistical analysis for 
significance was performed using GraphPad Prism 5 software. 
Histology and Inflammation Score 
At previously described post surgery time points, whole eyes were completely 
removed from the ocular cavity and immediately dissected to remove the cornea.  A 
central strip was cut from the surgically wounded section of the cornea and snap frozen 
using liquid nitrogen.  Frozen strips were held at -80°C for 3 hours and cryosectioned 
using a Zeiss Microm HM 505N Cryostat.  Cornea sections were then air dried and H&E 
stained using a Leica AutoStainer XL.  Images were taken at 10x and 40x magnifications 
using a Nikon SMZ 1500 light microscope.  Slides were then blind scored for 
inflammation using a 0-10 scale based on a previously published protocol modified for 
corneal tissue (Singh et al, 2003).  Each sample was analyzed for cell infiltration, 
irregularities in cell shape, breakage of epithelial cells, and presence of vacuoles.  A score 
of 0-2 indicated no cellular infiltrates/intact epithelial layer, 2-4 few infiltrates/breakage 
in the epithelial layer, 4-6 many infiltrates/non-intact epithelium, and 6-10 represents 
highly inflamed tissue.  As reference controls, corneas receiving no treatment were taken 
immediately post-surgery, sectioned, and also scored with the treated samples.  Statistical 
analysis was performed using a two-tailed student’s t-test with p<0.05 set as significant.  
RT-PCR of Epithelial-Mesenchymal Transformation Pathway Genes 
Corneas were sectioned at 1, 3, and 21 day time points for each of the pluronic 
gel, control peptide, αCT1, and αCT1 A-PLO microcapsule treatments.  Entire corneas 
were cut into sections, with individual ¼ sections placed in 1mL of Trizol Plus RNA 
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purification reagent (Invitrogen), and processed according to manufacturer’s protocol.  
Extracted RNA was tested for quality and quantity using an Agilent 2100 bioanalyzer and 
Agilent RNA 6000 nano kit (Agilent Technologies, Inc).  Two random samples of RNA 
per treatment type were selected for each of the three (1, 3, 21 days) time points making 
sure no two RNA samples were selected from the same rat source in the same treatment 
group.  These samples were then converted to cDNA at a concentration of 250nM using a 
BioRad iScript cDNA kit (Bio-Rad Laboratories) according to manufacturer’s 
instructions. Gene specific primers for Krt19, ZO-1, and Cx43 of the EMT pathway were 
designed using BLAST web based software and synthesized commercially by IDT 
technologies (Table 3.1).  The gene attachment region binding protein (ARBP) was used 
as a calibrator reference.  Primers were tested for efficiency using RNA from day 3 
pluronic gel treated rats and optimized using PCR gel analysis (data not shown).   
 Real-time PCR was run with each gene according to a previously published 
protocol (Valarmathi et al, 2009) using a MyiQ single color real time PCR detection 
system (Bio-Rad Laboratories) with SsoAdvanced SYBR Green supermix, 3pmol/rxn 
primers and 1µl cDNA. All data were analyzed using the Relative Expression Software 
Tool (REST XL), with pluronic gel treated samples serving as the baseline control.  
Statistical analysis was performed using both the REST XL and GraphPad Prism data 







Table 3.1 RT-PCR Primer Sequences 
Gene Forward Primer Reverse Primer  BP 
ARBP 5'-CGACCTGGAAGTCCAACTAC-3' 5'-ATCTGCTGCATCTGCTTG-3' 109 
Cx43 5'-TCAGCCTCCAAGGAGTTCCACCAAC-3' 5'-GCACTGACAGCCACACCTTCCC-3' 159 
Krt19 5'-AGCATGAAAGCTGCCCTGGAA-3' 5'-ATACTGCTGATCACACCCTGGA-3' 92 
ZO-1 5'-CCATCTTTGGACCGATTGCTG-3' 5'TAATGCCCGAGCTCCGATG-3' 123 
 
Immunofluorescence Staining and Confocal Microscopy 
Whole eyes were removed and fixed in 2% paraformaldehyde at 4°C for 24 hrs.  
Corneas were dissected from the eye to remove the cornea, with each cornea cut into four 
equal ¼ sections. Immunofluorescence preparation was performed and staining was 
carried out on single ¼ sections, including portions of the injury site, as previously 
described (Valarmathi et al, 2009). Primary antibody dilutions used for 
immunofluorescence staining are listed in Table 3.2.   Staining was performed for 1 hr at 
RT in the dark with the exception of DAPI (30 minutes) and anti-Cx43 (2 hours).  Alexa 
Fluor 488 (Molecular Probes, Invitrogen) secondary antibodies were added in dilutions of 
1:100 in blocking buffer for 1 hour at RT in the dark. Images were obtained with a Zeiss 
LSM 510 Meta CSLM microscope.  Negative controls using only secondary antibodies 








Table 3.2 Primary antibodies used in confocal microscopy immunohistochemistry 
Primary Antibodies Dilutions Manufacturer Purpose of Interest 
Phalloidin (Alexa Fluor 546) 1:100 Invitrogen F-actin marker of cytoskeleton 
DAPI (4',6-diamidino-2-phenyl-indole) 1:1000 Invitrogen Nuclei marker 
Phospho-Histone H3 (Ser28) 1:200 Cell Signaling Cell migration 










Migrating cells in EMT 
Inflammatory cytokine 
Chemokine/activated T cells 
 
3.4 Results 
3.4.1 Microcapsule Release and Biocompatibility Analysis 
This study compared wound healing of a directly applied dose of 150µM αCT1 vs. 
controlled αCT1 release through A-PLO pH 4.3 microcapsules at the same concentration.  
Previous studies using αCT1 showed the peptide was metabolized within 2hrs of 
application in vivo (Rhett et al 2011), leading to development of a method for sustained 
release.  For proof of concept, FITC labeled αCT1 is shown microencapsulated in 180µm 
microcapsules in fig. 3.1A.  Our previously results in chapter 2, summarized in fig. 3.1B, 
show A-PLO pH 4.3 microcapsules synthesized at an initial concentration of 200µM 
released an average of 113.99 ± 42.85µM αCT1 over a 48hr period.  In these tests, the 
small size of αCT1 led to a rapid burst release of 80% of the αCT1 in the first two hours 
from 2% alginate microcapsules.  Polymer coating of the 2% alginate with 0.5% poly-l-
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ornithine, combined with a reduction in pH from an initially tested 7.4 to an acidic 4.3, 
led to a delay in release over 48hrs, rather than an initial burst. All microcapsules in these 
results were synthesized at a 6.0kV voltage/60mm/hr flow rate, which was used in these 
in vivo studies.   
To ensure microcapsule biocompatibility, we performed an XTT cytotoxicity assay 
using RLECs treated with A-PLO microcapsules at both neutral and acidic pH values, 
uncoated 2% alginate microcapsules pH 7.2, and 150µM αCT1.  In addition, a 2% 
solution of media/0.15M CaCl2 used in the microcapsule synthesis gelling bath was 
tested. The graph in fig. 3.1C shows the cell optimization of XTT used to determine the 
ideal RLEC count, (determined to be 60,000 cells per well) based on the linear region. 
Treatment with the microcapsules from this study (A-PLO pH 4.2) and two additional 
microcapsule types (alginate alone and A-PLO pH 7.2) with variations in both pH and 
material type provided an examination of the in vitro cellular reaction of each of the 
synthesizing materials/solutions. Percent survival values shown in fig. 3.1D were as 
follows; 2% CaCl2 showed a 80.90 ± 5.42% survival, A-PLO pH 4.2 a 92.05 ± 3.25% 
survival, A-PLO pH 7.2 a 99.19 ± 0.99% survival, 150µM αCT1 a 91.75 ± 4.74% 
survival, and 2% alginate microcapsules pH 7.2 a 96.46 ± 1.97% survival. Buffering the 
pH in A-PLO microcapsules from a neutral pH of 7.2 to an acidic pH of 4.2 showed a 
negative effect on cell survival, with a reduction of 7.14%.  Comparatively, uncoated 2% 
alginate microcapsules showed a 4.41% higher survival rate at a neutral pH 7.2 than the 
A-PLO pH 4.2 capsules.  The lowest survival percent was shown when a 2% CaCl2 






Figure 3.1 Summary of in vitro release and reactivity of alginate-polymer microcapsules. 
(A) 20X phase contrast image of microencapsulated FITC labeled αCT1 peptide. (B)  
Release profile of A-PLO microcapsules pH 4.3.  Data represents four independent trials. 
(C) Cellular optimization graph using rabbit lens epithelial cells treated with XTT/PMS 
over 24hrs.  The linear region indicates optimal cells tested.  (D) XTT cytotoxicity test 
results of polymeric microcapsules and calcium chloride on 60,000 rabbit lens epithelial 











3.4.2 Analysis of Corneal Wound Closure  
      Having determined the optimal microcapsule profile and determined the 
biocompatibility of the encapsulating materials, we next sought to test them in an in vivo 
wound model. Cornea measurements of wound closure rates for all four treatments at 
each of the time points (post surgery, 1, 3, 10, 21, 30 days) were evaluated through 
imaging of GFP labeled Fluress ophthalmic dye on the wounded corneas.  Using a Zeiss 
Lumar V12 stereomicroscope and Axiovision software we captured and measured the 
area of the wound at each time.  For each treatment 25 randomly selected eyes were 
measured.  Our results indicated at the 10, 21, and 30 day time points the wounds had 
reached complete closure in all tests (day 10 shown in fig. 3.2, while day 21 and day 30 
not shown).  Samples of these wound closure images are shown in figure 3.2 for day 0 
(post surgery), day 1, and day 3, while the averaged results are listed in table 3.3.  The 
results in table 3 indicate the percent change in wound area of the final day 1 or day 3 
measurements subtracted from the initial day 0 measurements, as indicated in the table.  
Each of the treatments were analyzed using the Grubb’s test for outliers with significance 
set to p<0.05 to remove any non-significant data points.   
Examining the results in table 3.3, the largest change in wound closure rate 
occurred in the first 24hrs after surgery.  The treatment group receiving direct application 
of αCT1 showed an average increase in wound closure of 31.92% vs. pluronic controls, 
while those receiving αCT1 A-PLO microcapsule treatments showed a 49.92% increase 
in wound closure compared to pluronic controls.  From the 24-72hrs time points, αCT1 
treated corneas saw an additional 17.40% increase in wound closure. The αCT1 A-PLO 
microcapsule treated corneas dropped below the rate of the direct αCT1 values at this 24-
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72hr time period, but still increased wound closure 10.16% faster than pluronic treatment.  
Based on the release profile of the A-PLO microcapsules, we found ~93% of 
encapsulated αCT1 was released within the first four hours, as shown in fig. 3.1B.  This 
is an improvement on the rapidly metabolized direct application of αCT1 shown through 
previous in vivo studies, as previously referenced, and believe it accounts for the changes 
in wound closure rates for the A-PLO treatments. Additional graphical representation of 
the percent difference in wound closure from table 3.3 is provided in Appendix A.2, with 
results indicating significant differences at 1 day for reverse, αCT1, and αCT1 
microcapsule treatments as well as 3 day αCT1 microcapsule treatment compared to 
pluronic treatments.   
To further corroborate our wound closure data, samples of cornea taken at the 3 
day time point were cryo-sectioned and histologically stained with H&E.  These images 
indicate the epithelial layer was completely removed during surgery, exposing the 
stroma. We were able to visualize the cell number of the epithelial layer by examining the 
stained nuclei.  Images taken at 40x magnification shown in figures 3.3B, D, F, and H 
show that the epithelial layer has reached ~4-5 cells thick by the 3 day time point in 
regions of the cornea that have completely healed.  Normal full thickness cornea has an 
epithelial layer of 5-6 cells.  Comparing the four treatment groups there are no visible 
changes in the epithelial layer from treatment to treatment; i.e. increased layer thickness 
caused by increased corneal wound healing resulting from addition of αCT1 and A-PLO 
treatments. Sample images of untreated cornea wounds taken immediately post surgery 
are shown along the wound edge (Fig. 3.3I refer to all figures and in order (10x)) and 
within the wound margin (Fig. 3.3J (40x)). We conclude corneal healing approached both 
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complete wound closure and full thickness reepithelialization at 3 days post surgery.  
Complete wound closure and full thickness reepithelialization were seen by 10 days post 
surgery (not shown). 
To assess changes in the level of inflammation following treatment of the cornea 
we performed a blind inflammatory scale assessment. Both αCT1 treated and A-PLO 
αCT1 microcapsule treated were blind scored on a 0-10 inflammation scale against 
pluronic treated and untreated post surgical samples.  Five randomly chosen slides of day 
3 corneas were imaged from each of the four treatment groups and given a score based on 
the previously listed criteria. Figure 3.3K indicates the average values of each score with 
SEM.  Untreated post surgical control samples had an average score of 0.5, while 
pluronic treated averaged 8.18, indicating a high level of inflammation.  The αCT1 
treated (4.17) and A-PLO αCT1 microcapsule (4.73) samples each showed moderate 
inflammation at 3 days. Statistical analysis indicated these values to be significantly less 














Figure 3.2 Progressive wound healing over 10 days in a rat corneal injury model.  
Fluress ophthalmic dye staining of corneal defects immediately after surgery. Repeated at 
1 day, 3 days, and 10 days.  Additional staining completed on days 21 and 30 (not 
shown).  Treatments from top to bottom on each eye: 25% pluronic gel, 150µM control 
peptide, 150µM αCT1, and 150µM A-PLO microencapsulated αCT1. 
 
Table 3.3 Summary of wound closure rates measured using Fluorescein ophthalmic dye.  
Each data point represents 25 randomly selected eyes from each treatment.  Grubb’s test 
for outliers used to remove points found non-significant (p>0.05). 
 
 Pluronic Treated 
Control Peptide 
Treated αCT1 Treated 
αCT1 Microcapsule 
Treated 
% change 0-24hrs 38.86 ± 27.12 52.32 ± 29.59 70.78 ± 22.43 88.78 ± 12.69 
% change 24-72hrs 76.70 ± 19.60 89.59 ± 8.15 94.1 ± 10.08 86.86 ± 19.72 






Figure 3.3 Histological cryo-sectioning and staining of day 3 corneas using hematoxylin 
and eosin.  Each row contains a representative cornea sample for each treatment at 10x 
magnification (left) and 40x magnification (right).  (A, B) 25% Pluronic gel treated, (C, 
D) 150µM control peptide treated (E, F) 150µM αCT1 treated (G, H) 150µM A-PLO 
microencapsulated αCT1 treated. Images I and J show a 10x (left) and 40x (right) time 0 
untreated cornea for comparison.  The images are labeled with E, to mark the epithelial 
layer, and S for the stromal layer. (K) Summary of inflammatory scoring for time 0 










3.4.3 Examination of Wound Healing Response by RT-PCR and 
Immunohistochemistry  
The biochemical response of the wounds to the treatment groups was analyzed by 
focusing on genes from the epithelial to mesenchymal transformation (EMT) pathway 
and those specific for the Cx43-ZO-1 interaction. Reepithelialization of the cornea 
involves gap junction and tight junction remodeling, thought to be affected by the 
presence of αCT1.  Therefore, we hypothesized as corneal cells undergo remodeling and 
healing there would be a measureable change in EMT genes. 
Genes for Cx43, Krt19, and ZO-1 were analyzed by RT-PCR at 1 day, 3 day, and 21 
day samples from all treatment groups.  These time points were selected to analyze the 
immediate impact of the treatments (1 day), the impact at near wound closure (3 days), 
and the long term impact (21 days).  The results are summarized in fig. 3.4 using pluronic 
treated samples at each time point as baseline controls.  On day 1, all treatments caused a 
down regulation of Cx43, with both αCT1 (-1.80) and A-PLO (-1.61) capsules less than 
the control treatment (-2.05).  Cx43 is known to be down regulated immediately after a 
wound response, consistent with our data at 1 day. By day 3 all three treatment groups 
were up regulated in the Cx43 group (control: 1.12, αCT1: 1.60, and A-PLO: 1.50) with 
αCT1 treatment statistically significant (p<0.05).  The 21 day treatment group showed 
biphasic results between the control group and the two αCT1 treatments (control up 2.16 
fold, αCT1 down 1.16 fold, and A-PLO down 1.31 fold).  The results of ZO-1 at day 1 
and 3 were consistent with the data for Cx43 in all treatment groups with down regulation 
at day 1 (control down 1.98 fold, αCT1 down 1.18 fold, and A-PLO down 1.44 fold) and 
up regulation at day 3 (control up 1.27 fold, αCT1 up 1.21 fold, and A-PLO up 1.24 fold). 
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Our third examined gene, Krt19, is a stemness related marker thought to be down 
regulated during the EMT process, through roles in cell migration (Kong et al, 2010; 
Zhou et al, 2008).  Aomatsu et al (2012) were able to confirm down regulation of Krt19 
using Snail and Slug overexpression in human corneal epithelial cells (Aomatsu et al, 
2012; Ma et al, 2010). Here we show an immediate up regulation of Krt19 at day 1 in all 
treatments, with significance in both αCT1 (up 3.49 fold) and A-PLO treatment (up 2.57 
fold) groups.  By day 3 and continuing to day 21, Krt19 is consistently down regulated 
with significance shown at day 3 A-PLO treatment (down 3.66 fold).   
Confocal microscopy using Krt19 (Fig. 3.5 A and B) and Cx43 (Fig. 3.5 C and D) 
was performed to validate the RT-PCR results.  Figure 3.5 shows sample images of day 1 
and day 3 A-PLO treated corneal wounds.  Arrows mark the reepithelializing wound 
margins in each image.  Day 1 staining with Krt19 was expressed along the progressing 
wound edge as seen in fig. 3.5A.  Later time points with day 3 and day 21 (not shown) 
Krt19 staining showed little to no presence in all images.  Cx43 antibody staining also 
produced staining similar to the results seen in the RT-PCR data.  Minimal Cx43 staining 
is shown in fig. 3.5C at day 1, while abundant within and around the wound margins at 
day 3, as viewed in fig. 3.5D.  This data further confirms our results for day 1 and day 3 





Figure 3.4 RT-PCR analysis of corneas for gene expression of Cx43, Krt19, and ZO-1. 
Each time point is represented in the corresponding graphs for day 1 (top), day 3 (middle) 
and day 21 (bottom).  Pluronic treated corneas serve as the baseline control, with the data 
presented for the up and down regulation of control peptide treated, αCT1 treated, and 





Figure 3.5 Confocal microscopy of 1 day and 3 day cornea samples receiving treatment 
with αCT1 A-PLO microcapsules. All images are at a 20x magnification. (A) 1 day 
cornea: Blue-DAPI, Green-Keratin 19, Red-Phalloidin   (B) 3 day cornea: Blue-DAPI, 
Green-Keratin 19, Red-Phalloidin (C) 1 day cornea: Blue-DAPI, Green-Connexin 43, 










3.4.4 Corneal Response to A-PLO Microcapsules  
Treatment with αCT1 A-PLO microcapsules increased the rate of wound closure, but 
initially created a minor inflammatory response during healing in a small number of 
treated rats.  Examples of the regions of affected tissue are shown in the upper and lower 
left images of fig. 3.6.  The resulting tissue was first seen in day 3 corneas with minimal 
to no presence at day 30.  Samples of corneal tissue exhibiting this affected tissue were 
stained for the inflammatory markers TNF-α and ITAC (CXCL11). CXCR3 (chemokine 
C-X-C motif receptor 3) is a receptor expressed during inflammatory responses and 
associated with activated T cells as well as NK cells (Ondeykal et al, 2005).  ITAC is an 
associated chemokine, active in the regulation of CXCR3 and up regulated during 
immune response.  TNF-α, along with IL-6 and IL-1, is a well known pro-inflammatory 
cytokine and marker of immune response.  Smooth muscle actin staining served as a 
cytoskeletal structural marker.  The pro-inflammatory markers shown in fig. 3.6A (TNF-
α) and fig. 3.6B (ITAC) were both expressed in tested corneas at 3 days with reduced 
presence by 30 days (not shown).  Comparing the results shown here with the cytoxicity 
data from fig. 3.1D we saw a different response in vivo and in vitro to A-PLO 
microcapsules pH 4.2.  Additional rats were tested with either 10µL drops of 0.15M 
CaCl2 or 10µL aliquots of triple DI water rinsed A-PLO pH4.2 microcapsules.  Only rats 
receiving the CaCl2 treatment continued to exhibit the inflammatory response.  We feel 
that the natural progression of the corneal injury coupled with residual CaCl2 applied to 
the wound with the A-PLO microcapsules during treatment produced the inflammatory 
response.  Subsequent corneal injury studies performed in the laboratory did not produce 
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any inflammatory reaction with microcapsule treatment when extensively rinsed with 



















Figure 3.6 The inflammatory response of the rat cornea to the αCT1 A-PLO 
microcapsule treatment in limited rats. Images are shown in both the upper left and lower 
left of the figure showing two representative portions of the affected tissue of the cornea 
at 30 days. (A) Confocal image at a 20x magnification of the affected tissue in a 3 day 
microcapsule treated cornea. Green-TNF-α, Red-smooth muscle actin. (B) 20x 
magnification of the affected tissue in a 3 day microcapsule treated cornea. Green-ITAC, 


























Examining the cytotoxicity of the A-PLO microcapsule synthesis related materials we 
found a high level of biocompatibility in vitro. Percent survival values using RLECs 
indicated a >92% survival with all materials (A-PLO pH 4.2, A-PLO pH 7.2, 2% alginate 
microcapsules pH 7.2, 150µM αCT1) except 2% CaCl2 which showed a 80.90 ± 5.42% 
survival. Buffering the pH in A-PLO microcapsules from a neutral pH of 7.2 to an acidic 
pH of 4.2 showed a small negative effect on cell survival, with a reduction of 7.14%.  
Comparatively, uncoated 2% alginate microcapsules showed a 4.41% higher survival rate 
at a neutral pH 7.2 than the A-PLO pH 4.2 capsules.  The lowest survival percent was 
shown when a 2% CaCl2 solution was tested.  Based on this result, extensive washing of 
the CaCl2 gelling solution from the microcapsules post synthesis is necessary when 
applying the microcapsules in vivo.  As a result of >90% survival in all XTT trials, the A-
PLO microcapsules were considered to be biocompatible for the corneal studies.  The 
relatively small reduction in cell survival created by lowering the pH from 7.2 to 4.2 
allowed for a high overall survival rate, while reducing the microcapsule pore size and 
extending αCT1 release.  
The results of the wound closure analysis indicated controlled release of αCT1 over 
the first four hours enhanced the wound healing rate of the microcapsule treated corneas 
18% over direct αCT1 treatment.  Direct αCT1 treated corneas received a onetime 
peptide application to the wound of 150µM, while microcapsule treated corneas received 
αCT1 release in the same dose for the full 24 hrs.  At the 1 day point the rats in all 
treatment groups received a second treatment.  It is thought that the first 24-36 hrs are the 
period when αCT1 is most functional in affecting gap junction formation in the healing 
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wounds.  As a result αCT1 treated corneas receiving a direct dosage of 150µM of the 
peptide show a greater wound closure rate than A-PLO treated corneas receiving an 
extended amount of αCT1 over this 24-72 hr time (i.e. directly applied αCT1 is actually 
more prevalent in the wound very early based on the slower release of the peptide from 
the microcapsules over 48hrs). Additionally, a large standard error resulted when 
evaluating the 24-72 hr period, which is thought to further account for differences in the 
direct αCT1 and A-PLO treatment final values. Looking at the total wound closure over 
the first 3 days (0-72hrs) the αCT1 A-PLO microcapsule treatment showed the fastest 
overall wound closure speed, reaching nearly complete closure of 99.15% (14.55% faster 
than pluronic treatment) on average.  This was followed by a 97.16% (12.56% faster than 
pluronic treatment) closure rate of αCT1. As a result, we hypothesize that αCT1 
treatment by A-PLO microencapsulation leads to a faster wound closure rate for corneal 
wound injuries over the complete time period.  While direct αCT1 treatment in the 24-72 
hr period is faster, the values indicated over the total 3 day time period showed a nearly 
complete closure (99.15%) when using A-PLO microcapsule treatment (Table 3.3). 
To examine inflammatory response of the cornea to treatment, αCT1 treated and A-
PLO αCT1 microcapsule treated cyrosectioned samples were blind scored on a 0-10 
inflammation scale against pluronic treated and untreated post surgical samples A 
significant decrease in inflammation was found when compared to pluronic treated 
control samples. Inflammatory scoring was performed to ensure the αCT1 treatment 
groups were providing no additional inflammatory response exceeding those found in the 
control groups.  On the contrary we saw less inflammation at the 3 day mark with these 
treatments.  The addition of αCT1 increased the wound healing rate and therefore by the 
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3 day time point moved beyond the inflammatory stage of healing faster than pluronic 
treated samples. Coupled with the XTT cytotoxicity data, we found little negative 
compatibility issues when treating with αCT1 and A-PLO microcapsules in vivo. 
Barker et al (2002) found in cardiac myocytes that Cx43 and ZO-1 were present in 
low amounts in normal tissue but were expressed and co-localized upon tissue disruption.  
Here we show, through our RT-PCR data, a similar down regulation in corneal wound 
healing of ZO-1 consistent with typical Cx43 action.  Between this 24 and 72 hr time 
point as the wound is healing, Cx43 and ZO-1 are up regulated as cell-cell adhesion and 
gap junction formation is recurring.  By day 21 there was a departure from this 
consistency.  The control group was shown to be up regulated in both Cx43 and ZO-1, 
while both αCT1 and A-PLO treatments showed Cx43 (down regulated) and ZO-1 (up 
regulated) no longer consistently co-expressed.  While not statistically significant, this 
departure is of note. 
The immediate up regulation in the RT-PCR data of Krt19 at day 1 is provocative, as 
the wound closure data shown in figures 3.2 and 3.3 indicated rapid re-epithelialization.  
Down regulation of the gene at 3 and 21 days follows the known EMT patterns, as the 
wound is continuing closure and completion of healing of the multi-layered corneal 
epithelium. This data suggests immediately after wounding a transmigration stage of re-
epithelialization is occurring rather than an EMT proliferation of cells from the limbal 
region. Based on the levels of up regulation, Krt19, as well as other cytokeratins, play a 
role in the re-epithelialization of corneal wounds. The treatment of corneal wounds with 
αCT1 is hypothesized to have resulted in an up regulation of migration of epithelial cells.  
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Finally we examined to minor response to A-PLO microcapsules in vivo looking at 
confocal immunohistochemistry of ITAC and TNFα. It is believed that a natural 
progression of the corneal injury coupled with residual CaCl2 from the gelling bath 
applied to the wound with the microcapsules during treatment produced the inflammatory 
response in a small number of rats.  This data is consistent with the results of the XTT 
cytotoxicity experiment previously listed. The results of subsequent corneal injury studies 
performed in the laboratory did not produce any inflammatory reaction with 
microcapsule treatment when the microcapsules were extensively rinsed with deionized 
water prior to application in the eye.  
3.6 Conclusions 
Treatment of corneal wound injuries with αCT1 peptide increased wound closure 
speed.  The addition of a polymeric αCT1 A-PLO microcapsule system further increased 
the wound healing speed over αCT1 alone.  Use of poly-l-ornithine as a polymeric drug 
delivery system was shown to be biocompatible, while the CaCl2 gelling solution was 
found to be cytotoxic in vivo.  Future use of this cationic crosslinking solution will 
require extensive washing with deionized water to ensure complete removal. 
Examination of Cx43 and ZO-1 in the corneal wound healing process showed results 
similar to previously published cardiac myocyte data, suggesting Cx43 and ZO-1 are 
coupled through down regulation immediately after injury or gap junction disruption, and 
are linked in up regulation during the healing process.  Krt19 was shown to be 
significantly expressed 24hrs after wounding with αCT1 and αCT1 A-PLO treatment.  
This EMT related protein may play a role in both migration of epithelial cells 
immediately after wounding and down regulation during a later EMT stage of cellular 
77 
 
proliferation by day 3 post injury.  Treatment with αCT1 may play a role in the early 
effects of migrational stages of corneal healing, as well as EMT pathway genes.   
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    CHAPTER 4: APPLICATION OF THE αCT1 PEPTIDE BOTH DIRECTLY 
AND THROUGH CONTROLLED RELEASE IN A TYPE I DIABETIC 
CORNEAL INJURY MODEL 
 
4.1 Abstract 
The αCT1 peptide is a synthetically produced mimetic modified from the DDLEI 
C-terminus sequence of connexin 43.  Previous research using various wound healing 
models have found promising therapeutic effects when applying the drug, resulting in 
increased wound healing rates and reduced scarring. Previous data suggested a rapid 
metabolism rate in vitro, creating an interest in long term release. Using a streptozotocin 
(STZ) type I diabetic rat model with a surgically induced corneal injury, we delivered 
αCT1 both directly, in a pluronic gel solution, and in a sustained system, using polymeric 
alginate-poly-l-ornithine (A-PLO) microcapsules, previously characterized in chapter 2.  
Fluorescent staining of wound area over a 5 day period indicated a significant increase in 
wound closure rates for both αCT1 and αCT1 microcapsule treated groups, with αCT1 
microcapsule groups showing the most rapid wound closure overall. Analysis of 
inflammatory reaction to the treatment groups indicated significantly lower levels of both 
ITAC and TNFα markers using confocal quantification and Elisa assays. Additional 
analysis examining genes selected from the EMT pathway using RT-PCR and Western 
blotting suggested αCT1 modification of TGFβ2, Krt8, Esr1, and Glut4 over a 14 day 
period.  Combined, this data indicates a possible suppression of the inflammatory 




 Type I diabetes, also known as diabetes mellitus, is a common disease 
characterized by hyperglycemia resulting from a deficiency in insulin production.  In this 
diabetic state, β-cells in the pancreas produce little to no insulin.  For the STZ model of 
type I diabetes, mild to severe diabetic states are induced in a dose dependent manner by 
targeting the β-cells ability to function normally (Arora et al 2009; Soetikno et al 2011).  
Several secondary health problems are commonly associated with diabetes, including risk 
of stroke, impaired vision, diabetic retinopathy, glaucoma, diabetic ulcers, and decreased 
wound healing efficiency (Pradhan et al 2007, Rao et al 2010; Sweetnam et al 2012).  Of 
interest here is impaired wound healing ability. Research has shown decreased leukocyte 
and macrophage function, difficulties in ECM deposition, and slowed re-epithelialization 
(Lee Y.H. et al 2012) occurring in diabetic wound healing.  The αCT1 peptide is a novel 
wound healing agent we believe could be effective in treating diabetic wounds.    
In vivo, the cytoplasmic tight junction protein zonnula occludin-1 (ZO-1) binds at 
its PDZ-2 domain with the C-terminus of Cx43 (Duffy et al 2002; Rhett et al 2012).  
Previous results studying the Cx43-ZO-1 interaction in the heart found that intact 
ventricular myocardium exhibited a low level of ZO-1-Cx43 interaction (Barker et al 
2002). Wound formation leads to disruption in these interactions, which in turn creates 
changes in protein-protein interactions, affecting formation of gap junctions. To 
investigate this effect αCT1, a 25 amino acid sequence comprised of a 16 amino acid 
antennapedia domain connected to a 9 amino acid (RPRPDDLEI) sequence from the C-
terminus of Cx43, was synthesized (Rhett et al 2008, 2011). The antennapedia sequence 
is inactive in genetic activity and aids in cellular uptake. Connexins play a key role as 
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mediators of both cell growth and death and function in immune response, hematopoiesis, 
and development of progenitor cells (Herve et al 2004; Oviedo-Orta et al 2004; Vinkin et 
al 2011).  Binding of the C-terminus of Cx43 to ZO-1 is believed to affect cellular 
communication and gap junction remodeling in wound healing (Soder et al 2009).   αCT1 
acts as a competitive inhibitor of this binding (Hunter et al, 2005; Soder et al 2009), 
increases the rate of wound healing, and reduces scar tissue formation in multiple wound 
healing models (Ghatnekar et al, 2009; O’Quinn et al 2011; Soder et al 2009).  A control 
peptide, with the active C-terminus sequence reversed, was created with the inactive 16 
amino acid antennapedia portion unchanged.    
Epithelial Mesenchymal transition (EMT) is a biological method of cellular 
rearrangement and repair of damaged tissue where immobile cells used for structural 
integrity and boundary formation may be mobilized to an area of need (Lee et al 2006). 
Once the EMT process is complete the mesenchymal cells convert back to epithelial cells 
in the process called MET, or mesenchymal-epithelial transition.  Typically the EMT 
process is tightly regulated by the body, as in embryogenesis (Radisky 2005).  The EMT 
process is not as well understood in the eye, with differing opinions on the relat ionship 
with wound healing.  However, both Kawakita et al 2012 and Aomatsu et al 2012 were 
able to show the prevalence of EMT in the eye using cornea epithelial cells in relation to 
TGFβ and Slug signaling in recent studies. Similar results summarizing the occurrence of 
endothelial mesenchymal transitions in the cornea have been published as well (Lee J. et 
al 2012), leading to the belief that EMT is in fact occurring in the cornea during healing. 
  In this study we hypothesized that a controlled dose treatment with αCT1 
microencapsulated in A-PLO would produce a significant increase in wound healing 
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when applied to a diabetic corneal injury model.  Previous studies have not completely 
shown the method of peptide action.  Here we examine genes from the EMT pathway, 
selected for their relationship to potential points of peptide influence, such as 
proliferation, motility, inflammatory regulation, and morphogenesis. In vitro experiments 
probing control and αCT1 treated bone marrow stromal cell monolayers also indicated 
potential genes of interest; keratin 8, keratin 19, and TGFβ2. Additionally, we evaluated 
the roles of EMT associated genes related to insulin sensitivity by examining glucose 
transporter 4 (GLUT4) and estrogen sensitive receptor 1 (Esr1).  
4.3 Materials and Methods 
Induction of Type I Diabetes, Corneal Surgery, and Wound Treatment 
Induction of type I diabetes was performed by single dose I.P injections of STZ 
(Sigma Aldrich) at 65mg/kg in Sodium Citrate buffer pH 4.5 (Sigma Aldrich), given to 
male Sprague-Dawley rats (Harlan Laboratories) weighing 240-260 grams. After 
delivery, rats were given a 24hr equilibration period prior to STZ to injection.  After 
injection, a one week period was allowed for complete diabetic illness to take effect.  At 
the end of the one week period rats were fasted overnight (18hrs) then tested for blood 
glucose levels from the tail vein using a ReliOn Confirm blood glucose meter and ReliOn 
ultra-thin lancets.  Rats with blood glucose levels exceeding 225mg/dL were considered 
diabetic and used in this study.  
Surgeries were carried out according to the same protocol previously described in 
chapter 3.  All experiments were performed in compliance with the Guide for the Care 
and Use of Laboratory Animals by the National Academy of Sciences and University of 
South Carolina Animal Resources Facility guidelines. Post surgery, rats were placed into 
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one of four time point groups spanning a two week period; 1 day, 3 days, 5 days, or 14 
days.  These four time points were repeated for four separate treatments, with a total of 
80 rats used in the study (25 per treatment/5 per time point). At each time point a total of 
10 eyes were used with identical treatment in both eyes of each rat to eliminate eye to eye 
cross contamination.  Each treatment group contained two controls (pluronic gel alone; 
control peptide) and two treatments with αCT1 peptide (direct application in pluronic gel; 
αCT1 A-PLO microcapsules).  To ensure sustained delivery of peptide into the corneal 
wound, a pluronic gel carrier (Pluronic F-127, Sigma Aldrich) was used at a 
concentration of 25% w/v.  Control group rats received treatments of either 10µl 25% 
pluronic gel or 10µl of 150µM control peptide/25% pluronic gel.  Application of αCT1 
was again delivered at either 10µl 150µM αCT1/25% pluronic gel per eye or 150µM 
αCT1 Microcapsules/10µl 25% pluronic gel per eye with A-PLO microcapsules.  Each 
treatment was applied immediately after surgery (0 hrs), at 24 hrs, and at 72 hrs.  All rats 
were ethically sacrificed at the designated endpoints. 
Synthesis of αCT1 Loaded A-PLO Microcapsules 
Microcapsules were synthesized to match those used in chapter 3, according to 
the protocol previously detailed in chapter 2. Sterile sodium alginate (Sigma-Aldrich 
catalog#A0682, high maluronic acid content, low viscosity) poly-l-ornithine (Alfa Aesar 
L-ornithine hydrochloride 99%) microcapsules were synthesized and release of αCT1 
was measured.  All microcapsules were synthesized with a 2% alginate/0.5% PLO 
concentration and gelled in 0.15M calcium chloride (CaCl2) (Sigma-Aldrich) solution for 
12 minutes.  The synthesis parameters were constant at a needle to working bath distance 
of 7mm, a voltage of 6.0kV, and a flow rate of 60mm/hr.  Microcapsule solutions were 
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buffered to pH 4.3 using 0.1M HEPES and 0.1M hydrochloric acid (HCL). A-PLO 
microcapsules were loaded with αCT1 at an initial concentration of 200µM to match all 
microcapsules tested in chapter 3.  A summary of the release profile of the A-PLO 
microcapsules used here can be referred to in figure 3.1.1B. 
Wound Measurements and Analysis 
Assessment of wound area was carried out according to the same protocol 
described in chapter 3. In review, 2µl drops of Fluress (fluorescein sodium and 
benoxinate hydrochloride, Akorn Incorporated) GFP labeled fluorescent dye were placed 
on the wounded cornea and allowed to cover the eye surface.  Excess dye was removed, 
leaving a thin coat attached to the corneal surface.  Images were taken of the wound at 0 
hrs (immediately post surgery), 1 day, 3 days, 5 days, and 14 days, using a Zeiss Lumar 
V12 fluorescence microscope with a 20X objective and 1.5X lens magnification. All 
images were taken prior to application of treatments. The area of each wound site was 
measured using Axiovision Release 4.8.2 software. The percent decrease in wound area 
was calculated for each trial and treatment by comparing differences in wound area 
between initial and final measurements taken at each time point. Graphing and statistical 
analysis for significance was performed using GraphPad Prism 5 software analyzing the 
percent difference vs pluronic treated control groups and Kaplan-Meier survival analysis. 
Confocal Quantification of Inflammation Using ITAC and TNFα 
Cornea samples from all four treatments were fixed overnight at 4°C in 2% 
paraformaldehyde. Fixed samples were then stained for immunohistochemistry using 
antibodies for ITAC and TNFα according to a previously published protocol (Valarmathi 
et al, 2009). Staining was carried out 1hr at RT for both ITAC and TNFα on samples 
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from all four treatments at time points of 1 day, 3 days, and 5 days. Nuclear staining with 
DAPI diluted 1:2000 was also performed for 30 minutes.  Alexa Fluor 488 (TNFα) or 
546 (ITAC) (Molecular Probes, Invitrogen) secondary antibodies were then added at 
1:100 dilutions in blocking buffer 1hr. Images were obtained with a Zeiss LSM 510 Meta 
CSLM microscope of two separate regions within the wound margin where inflammation 
fluorescence was visualized for both ITAC and TNFα.  Pluronic gel treated samples from 
the 1 day time point were used to initially set the upper threshold settings for each 
inflammatory marker.  The reuse setting of the microscope was then applied to all 
subsequent images, allowing for identical microscope conditions at each treatment and 
time point.  Additionally, all samples were stained and imaged under identical conditions 
and at the same time to eliminate variation in processing and photo bleaching over time. 
Negative controls were created using samples stained with only secondary antibodies. 
 
Table 4.1 Summary of antibodies used for confocal inflammatory quantification. 
Primary Antibodies Dilutions Manufacturer Purpose of Interest 
DAPI (4',6-diamidino-2-phenyl-indole) 1:2000 Invitrogen Nuclei marker 
TNF-α 1:100 Phar Mingen Inflammatory Cytokine 
Anti-mI-TAC (CXCL11) 1:100 R&D Systems Chemokine/activated T cells 
 
Images were next analyzed using the ImageJ 1.45s software package (National 
Institutes of Health, Bethesda, Md).  Measurements were set to analyze mean intensity 
with limits to threshold and the threshold adjusted to create a binary image of the stained 
areas of inflammation. Binary images were then processed using the smooth function to 
solidify the edges.  Each measurement was performed in triplicate and recorded.  The 
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measurements were converted to percent of total coverage using the formula 100-((x-
255)*100), with x representing the measured value and 255 the maximum threshold limit.  
Values were graphed using the GraphPad Prism 5 software and statistical analysis using 
two way ANOVA comparing against pluronic treated samples with significance set at 
p<0.05.    
Elisa of Corneal Protein Using the Inflammatory Marker TNFα 
To validate the confocal inflammatory quantification data, Elisa (enzyme linked 
immunosorbant assay) was performed using the TNFα cytokine marker. Wounded cornea 
samples were dissected from all four treatment groups at 1, 3, and 5 days. Samples were 
homogenized and placed in a solution of T-PER tissue protein extraction reagent 
(Thermo Scientific) and Halt protease inhibitor (Thermo Scientific). The solutions were 
centrifuged at 10,000 g for 5 minutes. The resulting protein supernatant was analyzed for 
total concentration using a Coomassie assay (Thermo Scientific) according to 
manufacturer’s instructions on a BioTek Synergy 2 spectrophotometer. Elisa was then 
conducted in triplicate on protein samples using a rat TNFα ReadySET-Go! 
(eBioscience) kit according to manufacturer’s instructions.  The resulting relative protein 
concentrations were graphed using the GraphPad Prism 5 software and statistical analysis 
performed using two way ANOVA comparing against pluronic treated samples with 
significance set at p<0.05.    
RT-PCR of EMT Markers 
RT-PCR was performed in the same manner as described in chapter 3. Corneas 
were sectioned at 1, 3, and 14 day time points for each of the pluronic gel, control 
peptide, αCT1, and αCT1 A-PLO microcapsule treatments.  Entire corneas were cut into 
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sections, with individual ¼ sections placed in 1mL of Trizol Plus RNA purification 
reagent (Invitrogen), and processed according to the manufacturer’s protocol.  Extracted 
RNA concentration was measured using an Agilent 2100 bioanalyzer and Agilent RNA 
6000 nano kit (Agilent Technologies, Inc).  Two samples of RNA per treatment type 
were selected for each of the three (1, 3, 14 days) time points, ensuring no RNA samples 
were selected from the same rat source in the same treatment group.  These samples were 
then converted to cDNA at 250nM using a BioRad iScript cDNA kit (Bio-Rad 
Laboratories) according to manufacturer’s instructions. Gene specific primers for Keratin 
19, Keratin 8, and TGFβ2 of the EMT pathway and the insulin sensitive genes Esr1 and 
GLUT4, related to the EMT pathway were designed using BLAST web based software 
and synthesized by IDT technologies (Table 4.1).  The gene attachment region binding 
protein (ARBP) was used as a calibrator reference.  Primers were tested for efficiency 
using RNA from day 3 pluronic gel treated diabetic rats and optimized by PCR gel 
analysis (data not shown).   
Real-time PCR was run with each gene according to a previously published 
protocol (Valarmathi et al, 2009) using a BioRad CFX Connect single color real time 
PCR detection system (Bio-Rad Laboratories) with SsoAdvanced SYBR Green supermix, 
1µl cDNA, and 3pmol/rxn primers. All data was analyzed using the Relative Expression 
Software Tool (REST XL), with pluronic gel treated samples serving as the baseline 
control.  Statistical analysis was performed by both the REST XL Pair Wise Fixed 
Reallocation Randomization Test and GraphPad Prism data analysis software using 























GLUT4 5’-CTCTCAGGCATCAATGCTGTT-3’ 5’-GAGACCAACGTGAAGACGGTA-3’ 122 
Esr1 5’-AGTGAAGCCTCAATGATGGG-3’ 5’-CAAAGATCTCCACCATGCCT-3’ 281 
Krt8 5’-CTTCTCCCTAGTCACCCACT-3’ 5’-TTCCATGTTCGGTCTGCTTC-3’ 110 
TGFβ2 5’-GCCAATGTAGTAGAGGATGGCTC-3’ 5’-AAACTAACCACTTTCTTGCGTG-3’ 108 
 
Western Blotting of EMT Markers  
 Wounded cornea samples were dissected from all four treatment groups at 1, 3, 
and 14 days. Samples were homogenized and placed in a solution of T-PER tissue protein 
extraction reagent (Thermo Scientific) and Halt protease inhibitor (Thermo Scientific). 
The solutions were centrifuged at 10,000 g for 5 minutes. Resulting protein supernatant 
was analyzed for total concentration using a Coomassie assay (Thermo Scientific) 
according to manufacturer’s instructions on a BioTek Synergy 2 spectrophotometer. 
Solutions of 20ug/lane of protein mixed 1:1 with Laemmeli buffer/β-
mercaptoethanol were denatured at 70°C, then loaded onto BioRad Criterion 4-15% TGX 
12+2 gels. A volume of 20µL of BioRad Precision Plus was also loaded on each gel as a 
standard.  SDS-Page was then performed at 200V for ~40 minutes in Tris/Glycine/SDS 
buffer (Biorad).  Gels were next wet transferred by western blotting onto supported 
nitrocellulose membranes (BioRad) at 100V for 45 minutes in transfer buffer 
(Tris/Glycine buffer (BioRad) with methanol pH 8.0).  Blotted membranes were blocked 
for 1hr in a solution of 5% non-fat dry milk (BioRad) and PBS-Tween (Sigma), rinsed 
three times in PBS-Tween, and stained overnight at 4°C with primary antibodies (Table 
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4.3).  Antibodies were selected to match genes tested for RT-PCR; Krt19, Krt8, TGFβ2, 
Esr1, and GLUT4.  The Erk1 antibody was used as a reference control. Blots were then 
rinsed three times in PBS-Tween and stained 1hr with secondary HRP labeled antibodies 
(Invitrogen).  Blots were exposed 1 minute to Hyglo chemiluminescent HRP detection 
reagent (Denville Scientific Inc.) and images captured using a BioRad ChemiDoc XRS+ 
system with QuantityOne software.  Bands were measured for density with equal volume 
boxes applied to each blot to standardize total area.  Each time point was performed in 
duplicate for every antibody.  To compare the results from blot to blot, measurements 
were converted to values representing fold change analyzed against pluronic treated 
samples for 1 day, 3 day, and 14 day times. Results were then graphed using GraphPad 
Prism software with statistical analysis using two way ANOVA and p<0.05 statistically 
significant. 
Table 4.3 Summary of antibodies used for western blotting. 
Primary Antibodies Dilutions Manufacturer 
Krt19 1:500 Novus Biologicals 
Krt8 1:10000 Novus Biologicals 
TGFβ2 1:500 Santa Cruz Biotechnology 
Esr1 1:500 Santa Cruz Biotechnology 
GLUT4 1:500 Santa Cruz Biotechnology 
Erk1 1:1000 BD Biosciences 
 
4.4 Results 
4.4.1 Analysis of Diabetic Corneal Wound Closure 
 Examination of wound closure rate was conducted through fluorescent staining 
with an ophthalmic dye and subsequent measurements of the changing area of the corneal 
wounds.  A total of 25 eyes with measurements spanning the time points at 0 hrs, 1 day, 3 
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days, and 5 days were selected from each treatment group to determine the average 
change in wound area over time.  Additional measurements were also taken at 14 days 
but were excluded after near 100% closure was seen in all eyes by day 5.  Figure 4.1 
provides a visual summary of the wound closure rate while table 4.4 lists the average 
values for each treatment over the 5 day (120hr) period as percent change in wound area 
± SEM.  From this data we were able to conclude αCT1 treatment led to a faster wound 
closure rate than control treatments, while microencapsulated αCT1 treatment showed 
even greater wound closure speed. Statistical analysis of this data was conducted through 
two way ANOVA analysis of the differences in average wound closure vs pluronic 
treatment (p<0.05).  Figure 4.2A represents this data graphically with Figure 4.2C 
containing the specific numerical results.  Significant differences in wound closure were 
found in both αCT1 and microencapsulated αCT1 treatments at 1 day (20.83% and 
24.67% respectively) and 3 days (12.73% and 15.90% respectively).  In comparison no 
time points were found significant for control peptide treatments.  To further analyze the 
significance of the differences in both αCT1 and microencapsulated αCT1 treated wound 
closure we conducted a Kaplan-Meier survival analysis replacing percent closure with 
survival.  The results of this study are presented in Figure 4.2B and numerically in Figure 
4.2D. The curve pattern was conserved between the Kaplan-Meier and the percent 
difference data.  From figure 4.2D we saw by the 5 day period a complete closure of the 
wounds in all eyes for the αCT1 microcapsule treated rats.  The αCT1 treated wounds 
were at 90.41% closure, while control peptide treated were 36.55% closed.  Additionally, 
a Mantel-Cox analysis comparing the curves in figure 4.2B found both αCT1 and 
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Figure 4.1 Progressive wound healing over 5 days in a diabetic rat corneal injury model.  
Fluress ophthalmic dye staining of corneal defects immediately after surgery. Repeated at 
1 day, 3 days, and 5 days. Treatments from top to bottom on each eye: 25% pluronic gel, 
150µM control peptide, 150µM αCT1, and 150µM A-PLO microencapsulated αCT1. 
 
Table 4.4 Summary of diabetic wound closure rates measured using Fluorescein 
ophthalmic dye.  Each data point represents 25 randomly selected eyes from each 






αCT1 Treated αCT1 Microcapsule 
Treated 
% change 0-24hrs 44.69 ± 21.34 45.22 ± 22.80 65.52 ± 20.15 69.36 ± 14.02 
% change 24-72hrs 73.71 ± 26.60 80.97 ± 18.79 87.12 ± 18.70 97.67 ± 4.27 
% change 0-72hrs 83.04 ± 21.43 87.01 ± 16.09 95.77 ± 5.44 98.94 ± 2.10 






Figure 4.2 Diabetic corneal wound closure analysis of the (A) average percent 
differences in wound closure vs pluronic controls and (B) Kaplan-Meier survival analysis 
modified for percent closure over a 5 day period. Summaries of individual values for A 















4.4.2 Investigation of Inflammation Using Confocal Quantification and Elisa 
 We next set out to examine the effects of each treatment on inflammation over the 
first five days of wound closure. Two markers of inflammation, ITAC (CXCL11) and 
TNFα, were selected to stain representative cornea samples at 1, 3, and 5 days.  Using 
ImageJ software, mean intensity values were measured and converted to percent coverage 
of the entire image.  A total of 12 measurements per inflammation marker were analyzed 
with average values shown in Figure 4.3. 
 The results of ITAC examination at day 1 indicated ~30-40% total coverage for 
all treatments except control peptide (56.23 ± 4.07%).  By day 3 this trend continued with 
~30-40% coverage seen in all treatment groups.  By 5 days, as complete wound closure 
was approached, only pluronic treated corneas still showed values in the 30-40% range 
(32.96 ± 9.49%), with control peptide dropping to 14.05 ± 4.72%.  Both αCT1 and 
microencapsulated αCT1 treated corneas showed significant reduction compared to 
pluronic treated with values of 4.23 ± 1.22% and 11.39 ± 1.16% respectively.  Data from 
the confocal TNFα quantification showed values that were different overall, but shared a 
similar trend over the same three time points. At 1 day both αCT1 (43.29 ± 3.53%) and 
microencapsulated αCT1 (22.49 ± 5.02%) treated corneas showed values lower than 
those seen in both controls, with both significantly different compared to pluronic treated.  
The pattern of expression with TNFα was the same as ITAC at 3 days, with a spike in 
αCT1 (74.91 ± 2.16%) producing the highest levels.  This was followed by pluronic 
treated (27.24 ± 6.40%), control treated (52.12 ± 5.11%), and finally microencapsulated 
αCT1 treated (13.89 ± 1.12%) at the lowest expression.  By day 5, pluronic and control 
peptide treated corneas continued to show the highest values; also seen in the day 5 ITAC 
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results.  Additionally, αCT1 and microencapsulated αCT1 treated samples again showed 
significantly lower expression vs pluronic at 5 days, matching the results from 5 day 
ITAC as well. 
 To corroborate the confocal quantification data, Elisa analysis using antibodies 
for TNFα was performed, with results shown in Figure 4.4. The day 1 Elisa results 
followed the same pattern as those seen in confocal quantification, with pluronic treated 
samples having the highest concentration. Both αCT1 (26.08 ± 3.50pg/mL) and 
microencapsulated αCT1 (46.40 ± 15.23pg/mL) treated corneas showed values lower 
than those seen in both controls, with both being significantly different compared to 
pluronic treated.  By day 3, αCT1 treated samples again showed a spike while the other 
three treatments results varied in comparison to confocal quantification analysis. Day 5 
analysis saw no significant changes in the results of αCT1 and microencapsulated αCT1 
treated samples in comparison to the controls, but overall these two active treatments 





Figure 4.3 Confocal inflammation quantification over the first five days after wounding 
using antibodies for (A) ITAC and (B) TNFα.  Within each box are the graphical, 






Figure 4.4 Elisa analysis of TNFα concentration in 1, 3, and 5 day corneal protein 
samples.  
 
Table 4.5 Summary of TNFα Elisa results for 1, 3, and 5 day diabetic cornea samples. 
Results are the average concentration of TNFα in pg/mL ± SEM. 
 
  Pluronic Treated Control Peptide αCT1 Treated αCT1 Microcapsule Treated 
Day 1 315.15 ± 109.70 45.51 ± 20.90 26.08 ± 3.50 46.40 ± 15.23 
Day 3 29.80 ± 12.43 24.94 ± 0.94 82.21 ± 30.42 39.58 ± 5.39 












4.4.3 Examination of the EMT Pathway in Diabetic Wound Healing by RT-PCR 
and Western Blotting 
 Examination of both wound closure and inflammation data indicated a noticeable 
effect on corneal wound healing with both αCT1 treatments.  As a result RT-PCR and 
western blotting was performed on a set of genes selected from the EMT pathway and 
related genes known to be insulin sensitive, as a means of investigating possible reasons 
for the therapeutic results. Figure 4.5 summarizes the results of the RT-PCR analysis of 
the five genes of interest.  A consistent up regulation of Esr1, Krt8, TGFβ2, and GLUT4 
at days 1, 3 and 14 is seen, while Krt19 was down regulated at days 1 and 3.  
Significance, determined by a pair wise fixed random reallocation test, was found for 
only αCT1 microcapsule treatments at day 1 in Krt8, TGFβ2, and GLUT4. At day 3 
significant up regulation was found in both αCT1 and microencapsulated αCT1 treated 
samples with TGFβ2 and significance in Krt8 for αCT1 only.  By day 14 all genes were 
up regulated, with TGFβ2 and Esr1 significant in αCT1 treated samples.  All genes that 
were control peptide treated showed strong expression relative to both αCT1 and 
microencapsulated αCT1 groups at day 14.    
 Figures 4.6 and 4.7 represent the results of densitometry analysis of western blots 
from 1, 3, and 14 day samples for the same genes evaluated by RT-PCR.  All results are 
presented as fold change differences vs pluronic treated samples.  GAPDH was used as 
the internal control antibody for normalization. In all time points and treatments no 
values were found to be statistically significant fold changes in protein expression, 
however similar patterns of regulation matched the results found in RT-PCR 
quantification. Data from all three time points indicated similar up regulation of TGFβ2, 
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Krt8, and GLUT4 for αCT1 and microencapsulated αCT1 samples, as seen in the RT-
PCR data.  TGFβ2 was again up regulated through all three time points with values 
between ~1.2-1.4 fold different than pluronic treated, except at day 3 in control treated 
samples. Krt8 was inconsistently up regulated with biphasic results in the RT-PCR data, 
but significant up regulation was shown in microencapsulated αCT1 treated samples at 1 
day and αCT1 treated samples at 3 days. Densitometry measurements at 1 and 3 days 
showed Krt8 up regulated in αCT1 (1 day- 1.37, 3 days-1.30 fold up regulated) and 
microencapsulated αCT1 treated (1 day- 1.43, 3 days- 1.89 fold up regulated) samples 
compared to both pluronic and control peptide treated. Similar to the RT-PCR results, 
Esr1 showed consistent up regulation in the western data, with particularly higher results 
in day 14 samples treated with αCT1 (1.74 fold) and microencapsulated αCT1 (1.70 fold) 
treatements. Krt19 western analysis indicated down regulation at 1 day for all three 
treatments, similar to the RT-PCR results.  This deviated at days 3 and 14 with up 
regulation in the western analysis while the RT-PCR data showed down regulation at 3 
days and up regulation at 14 days for all treatments. GLUT4 analysis remained the same 
in both western and RT-PCR analysis pattern, where all treatments were up regulated 






Figure 4.5 RT-PCR examination of EMT and insulin sensitive genes in 1, 3, and 14 day 
diabetic corneas. ARBP used as a reference gene with pluronic treated samples serving as 





Figure 4.6 Western blot examination of EMT and insulin sensitive genes in 1, 3, and 14 
day diabetic corneas. (A) Pluronic treated (B) Control Peptide treated (C) αCT1 treated 





Figure 4.7 Western blot densitometric analysis of EMT and insulin sensitive genes in (A) 
1 day (B) 3 day and (C) 14 day diabetic corneas. Average results for each time point are 






 Corneal wound healing was found to approach complete closure in all four 
treatment groups by the 5 day time point, with pluronic gel treated samples averaging 
~90% closure, αCT1 ~99%, and αCT1 microcapsule 100%.  Statistical analysis using 
two way ANOVA to compare the percent differences in closure at each time point 
showed significant differences at days 1 and 3 for both αCT1 (20.83% and 13.41% faster 
than pluronic treated) and αCT1 microcapsule (24.67% and 23.96% faster than pluronic 
treated) treatment groups.  Additional statistical analysis using the Kaplan-Meier method 
with analysis by the Mantel-Cox test, comparing survival distributions of two samples, 
also indicated significant differences in the wound healing curves of each of the two 
αCT1 treatments.  The Kaplan-Meier method is typically used to estimate survival over 
time in cases such as cancer treatments in large groups of patients, while also accounting 
for difficulties and changes from patient to patient. This method is used to generate 
survival curves based on designation of alive/dead of each patient, followed by analysis 
of statistical differences in their patterns. Here this method was modified to replace 
alive/dead with open/closed in relation to corneal wound state.  Doing so, we were able to 
analyze the probability of these curves occurring in larger studies. Overall these results 
indicated application of the αCT1 peptide enhances wound closure in a corneal injury 
model.  Additional therapeutic effects in the form of increased wound healing rate 
(3.84% at 24hrs vs αCT1 alone) were shown to occur with the addition of controlled 
release A-PLO microcapsules containing αCT1.  These results match the wound healing 
patterns previously seen in non-diabetic corneal wound closure. Comparing the 
differences in closure between αCT1 and microencapsulated αCT1 at each of the three 
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measured points, 1, 3, and 5 days, there was a consistently faster rate of closure in 
microencapsulated samples (3.84%, 3.17%, and 0.56% respectively).  This led us to 
conclude A-PLO microencapsulated αCT1 provides a definite advantage in therapeutic 
treatment over direct αCT1 treatment. 
 Investigation of the mechanisms of αCT1 action to create enhanced wound 
healing speed was examined by looking at inflammatory levels over time and gene 
analysis from the EMT pathway.  The results of the Western blotting and RT-PCR data 
indicated a relationship among genes that were up regulated significantly with αCT1 
treatments in comparison to control treatments.  Each of these genes are known to play 
either a direct or indirect role in inflammatory regulation. From the RT-PCR and western 
analysis, Krt8 and TGFβ2 were consistently up regulated for both αCT1 and 
microencapsulated αCT1 treatments at the three time points. Interestingly TGFβ2 was the 
only gene up regulated throughout all points.  This cytokine directly limits the 
inflammatory response, promotes accumulation and proliferation of fibroblasts, and 
controls deposition of ECM for proper tissue repair (Carrington et al 2006). Specifically, 
Huh et al 2009 found TGFβ2 was highly expressed during chick corneal wound repair.  
Their data suggest TGFβ2 activates keratocytes to transform into fibroblasts, a known 
action of wound healing in the cornea.  These fibroblasts are then reverted back to 
keratocytes as the wound closes. Keratins are tissue specific proteins typically associated 
with the cytoskeleton of epithelial cells.  The estrogen receptor pathway is directly related 
to insulin sensitivity, type I diabetes, and the EMT process.  Krt19 is thought to be down 
regulated in EMT (Aomatsu et al 2011) and related to the estrogen receptor pathway 
along with Esr1. Both Krt8 and Krt19 have been shown to be present in the limbal 
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epithelial cells of the cornea and are normal markers in healthy cells (Fu et al 2001, 
Merjava et al 2009 and 2011, Pai et al 2010).  The Esr1 gene, or ERα, is important in 
protection against and reduction of inflammation, as well as glucose tolerance (Ribas et al 
2009, Ricchiuti et al 2009).  Glucose transporter 4, or GLUT4, in vivo levels are altered 
by the inflammatory activation of stress kinases (Simar et al 2012).  This action is 
impaired in diabetes and obesity. 
Both αCT1 treatment groups saw a significant decrease in inflammation by day 5 
as the wounds approached complete closure.  Specifically looking at the day 1 TNFα 
confocal results, we saw identical highest to lowest order between inflammation level and 
day 1 wound closure.  During this rapid wound closure period, pluronic treated samples 
were shown to exhibit the most inflammation and the least change in wound closure.  
This was followed in order by control peptide treated, αCT1 treated, and αCT1 
microcapsule treated, observing a direct coupling of inflammation levels to wound 
healing rate.  A deviation in this exact pattern was found at day 3, with a spike in αCT1 
levels for ITAC and TNFα. Overall when comparing the results at all three points for 
ITAC, TNFα and Elisa TNFα there was a pattern of lowered inflammation with αCT1 
and microencapsulated αCT1 treatments compared to control groups, which 
corresponded to the rate at which corneal wound closure occurs.     
We saw a mode of action where αCT1 stimulates multiple proteins responsible for 
inhibition of inflammation.  Combined with our inflammatory data investigating markers 
for ITAC and TNFα, αCT1 is thought to increase wound healing rates by creating a 
complex reduction in inflammation that is significantly different than control treatments.  
This reduced inflammatory response may allow a more rapid induction of epithelial 
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migration and proliferation.  Additional investigation of this reaction to αCT1 is required 
to make definitive statements, with a complex response to the peptide likely.   
4.6 Conclusions 
 Treatment of diabetic corneal wound injuries with αCT1 peptide increased wound 
closure speed significantly compared to control groups.  The addition of a polymeric 
αCT1 A-PLO microcapsule system further increased the wound healing speed over αCT1 
alone. A possible mechanism of αCT1 action was suggested, based on inflammatory and 
RT-PCR investigation of key EMT genes, indicating the activation of anti-inflammatory 
cytokines and proteins.  Suppression of inflammation may lead to a more rapid 




CHAPTER 5: SUMMARY AND FUTURE WORK 
Summary  
Microencapsulation of αCT1 by the electrospray method was shown to increase 
corneal wound healing speed compared to αCT1 directly applied in a pluronic gel 
solution in both diabetic and non-diabetic rat models. In the non-diabetic study, 
microencapsulated αCT1 led to wound closure 18% faster than αCT1 alone at 24hrs and 
1.99% faster at 72hrs.  Results from the diabetic study indicated a 3.84% increase at 
24hrs, 3.17% increase at 72hrs, and 0.56% increase at 120hrs.  Comparing the results, the 
decreased wound healing function of the diabetic rats impeded the ability of αCT1 to 
duplicate the drastic results seen in the non-diabetic model.  While in both cases αCT1 
significantly increased wound healing rates beyond the results seen in both control 
groups, we hypothesized the impaired inflammatory function of the diabetic rats coupled 
with our conclusions on the αCT1 mechanism of therapeutic action involving 
inflammatory suppression, directly led to the difference in wound closure results seen 
between the two corneal wound closure studies from chapters 3 and 4. Furthermore, our 
microencapsulation method provided a reproducible and biocompatible device to deliver 
αCT1 in a controlled manner.  Limitations in this method come from the difficulties in 
microencapsulating a small peptide such as the one tested here. In these studies use of 
two polymer coatings, three pH values of gelling solution, and variations in alginate 
concentration and peptide loading ratio led to the synthesis of the microcapsules created 
here.  A benefit and impediment to drug delivery system design is the vast number of 
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factors and parameters that can be adjusted, which in turn alter the physical, chemical, 
biological reactivity, and release characteristics of the microcapsules.  As a result, we feel 
a compatible and functional design was obtained and applied to these wound models with 
significant results achieved.  
This work proposed a unique synthesis of a drug delivery system for the αCT1 
peptide. Additionally two distinct, yet connected, models of wound healing in the rat 
cornea detailed the analysis of the effects of therapeutic application of αCT1 in vivo.  
Furthermore, we provided data summarizing the effects of the application of this drug in 
two delivery methods, with and without the presence of a disease state, and analysis 
through multiple microscopic, biological, and statistical methods.  Focus on both the 
inflammatory and EMT pathway genetic regulation led to a proposed method of αCT1 
action.  As a result, we feel this work provides a unique perspective in both the potential 
of αCT1 moving forward as a wound healing agent and the methods to which αCT1 
functions in vivo. 
Future Work 
 A complete and comprehensive analysis of the αCT1 peptide mode of in vivo 
action in wound closure is ongoing.  Presented here is a promising start to evaluating the 
mechanism of αCT1 action by evaluation of the EMT pathway and inflammatory 
regulation.  Studies focusing specifically on the mode of action with a broad range of 
EMT genes should be pursued. The EMT pathway itself is a complex relationship of 
interconnected pathways, which should be analyzed in more detail in order to determine 
the definite relationship that is occurring. The results presented here, coupled with 
previously published data, indicate a significant therapeutic potential with no visible 
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negative biological side effects. Additional animal models should be used to fully 
evaluate the potential of αCT1 in order to find the best transition from bench top to 
bedside application. At this time, potential wound model and disease states being 
investigated include diabetic ulcers, topical skin burn models, and type II diabetic 
knockout models. Continued research into further enhancement of the microcapsule 
design could also lead to significant increases in release time, which in turn could lead to 
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